<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001903.pub3" GROUP_ID="EPILEPSY" ID="206899081710085336" MERGED_FROM="" MODIFIED="2016-02-04 10:12:01 +0000" MODIFIED_BY="Ellen Dougan" REVIEW_NO="0027" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="14.0">
<COVER_SHEET MODIFIED="2016-02-03 15:45:33 +0000" MODIFIED_BY="Rachael Kelly">
<TITLE MODIFIED="2015-12-22 22:04:05 +0000" MODIFIED_BY="Anne Lawson">Ketogenic diet and other dietary treatments for epilepsy</TITLE>
<CONTACT>
<PERSON ID="13552" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Robert</FIRST_NAME>
<MIDDLE_INITIALS>G</MIDDLE_INITIALS>
<LAST_NAME>Levy</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>rob.levy1@nhs.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>The Croft Shifta Health Centre</ORGANISATION>
<ADDRESS_1>Belfield Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rochdale</CITY>
<ZIP>OL16 2UP</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-02-03 15:45:33 +0000" MODIFIED_BY="Rachael Kelly">
<PERSON ID="z1506241200181073162453113736487" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Kirsty</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Martin</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>kirsty.martin@thewaltoncentre.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nutrition and Dietetics</DEPARTMENT>
<ORGANISATION>The Walton Centre NHS Foundation Trust</ORGANISATION>
<ADDRESS_1>Lower Lane</ADDRESS_1>
<ADDRESS_2/>
<CITY>Liverpool</CITY>
<ZIP>L9 7LJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1401071346374641271438430441114" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Cerian</FIRST_NAME>
<MIDDLE_INITIALS>F</MIDDLE_INITIALS>
<LAST_NAME>Jackson</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>cjacks@liv.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Molecular and Clinical Pharmacology</DEPARTMENT>
<ORGANISATION>Institute of Translational Medicine, University of Liverpool</ORGANISATION>
<ADDRESS_1>Clinical Sciences Centre for Research and Education, Lower Lane</ADDRESS_1>
<ADDRESS_2>Fazakerley</ADDRESS_2>
<CITY>Liverpool</CITY>
<ZIP>L9 7LJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13552" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Robert</FIRST_NAME>
<MIDDLE_INITIALS>G</MIDDLE_INITIALS>
<LAST_NAME>Levy</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>rob.levy1@nhs.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>The Croft Shifta Health Centre</ORGANISATION>
<ADDRESS_1>Belfield Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rochdale</CITY>
<ZIP>OL16 2UP</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13539" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS>N</MIDDLE_INITIALS>
<LAST_NAME>Cooper</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Neurologist</POSITION>
<EMAIL_1>paul.cooper@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Clinical Neurosciences</DEPARTMENT>
<ORGANISATION>Salford Royal Hospitals NHS Trust</ORGANISATION>
<ADDRESS_1>Hope Hospital</ADDRESS_1>
<ADDRESS_2>Stott Lane</ADDRESS_2>
<CITY>Salford</CITY>
<ZIP>M6 8HD</ZIP>
<REGION>Greater Manchester</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 787 5482</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 787 5625</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-06-09 14:33:34 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="30" MONTH="3" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="3" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="3" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-01-20 14:29:52 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-01-20 14:29:52 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="3" YEAR="2015"/>
<DESCRIPTION>
<P>Three new studies (<LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK>; <LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>) have been included. Conclusions are unchanged</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-09-17 14:11:33 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="3" YEAR="2015"/>
<DESCRIPTION>
<P>Searches updated 30 March 2015</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-09-17 14:05:12 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-09-17 14:05:12 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>New Summary of Findings table added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-05-28 09:40:11 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>Review updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-05-28 09:40:18 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>This review has been updated. Four new RCTs have been included. Seven prospective studies and four retrospective studies were also identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-01-20 14:39:18 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2016-01-20 14:39:18 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-01-20 14:39:18 +0000" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This review update was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Epilepsy Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-02-03 15:51:09 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-01-12 11:19:41 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-10-19 11:42:20 +0100" MODIFIED_BY="Pratima Giri">Ketogenic and other dietary treatments for epilepsy</TITLE>
<SUMMARY_BODY MODIFIED="2016-01-07 11:43:09 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-01-07 11:43:09 +0000" NOTES_MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>Epilepsy is a disorder where recurrent seizures (fits) are caused by abnormal electrical discharges from the brain. Most seizures can be controlled by one or more antiepileptic medicines but seizures may not be helped by these medicines after a while (called drug-resistant epilepsy). For people who have drug-resistant epilepsy a special diet (called a ketogenic diet) may be considered. Ketogenic diets are high in fat and low in carbohydrate.</P>
<P>This review aimed to investigate the effect of a ketogenic diet on seizure control, cognition (e.g., learning, concentration and academic performance in children; learning, concentration and memory in adults) and behaviour. We also investigated the side effects of the diet and the number of participants who dropped out of the studies and the reasons for this.</P>
<P>
<B>Search date</B>
</P>
<P>This evidence is current to March 2015.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We searched medical databases for randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) of adults or children with epilepsy where a ketogenic diet was compared with other treatments. We found seven randomised controlled trials, with 427 participants. The trials were between three and six months long.</P>
<P>
<B>Key results</B>
</P>
<P>The short-term side effects of ketogenic diets included diarrhoea, constipation and vomiting. In the long term, heart heath could be affected.</P>
<P>All studies reported participants dropping out, due to lack of improvement in seizures and poor tolerance of the diet.</P>
<P>No studies reported upon the effect of ketogenic diets on cognition and behaviour.</P>
<P>Recently, other, more agreeable, ketogenic diets, such as the modified Atkins ketogenic diet, found similar effects on seizure control as those more restrictive ketogenic diets. However, more research is required.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>The studies included in this review were limited by small numbers of participants and they only included children; therefore, the quality of the evidence was low.</P>
<P>There is little research at present into the use of these diets in adults, therefore, more research is required in this area.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-01-20 14:52:16 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-01-07 11:42:23 +0000" MODIFIED_BY="[Empty name]">
<P>The ketogenic diet (KD), being high in fat and low in carbohydrates, has been suggested to reduce seizure frequency. It is currently used mainly for children who continue to have seizures despite treatment with antiepileptic drugs. Recently, there has been interest in less restrictive KDs including the modified Atkins diet (MAD) and the use of these diets has extended into adult practice.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-01-07 11:42:24 +0000" MODIFIED_BY="[Empty name]">
<P>To review the evidence for efficacy and tolerability from randomised controlled trials regarding the effects of KD and similar diets.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-01-07 11:42:29 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Epilepsy Group's Specialized Register (30 March 2015), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 30 March 2015), MEDLINE (Ovid, 30 March 2015), <A HREF="https://clinicaltrials.gov/">ClinicalTrials.gov</A> (30 March 2015) and the <A HREF="http://apps.who.int/trialsearch/">WHO International Clinical Trials Registry Platform</A> (ICTRP, 30 March 2015). We imposed no language restrictions. We checked the reference lists of retrieved studies for additional reports of relevant studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-01-07 11:42:29 +0000" MODIFIED_BY="[Empty name]">
<P>Studies of KDs and similar diets for people with epilepsy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-01-07 11:42:29 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently applied pre-defined criteria to extract data and assessed study quality.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-01-20 14:52:16 +0000" MODIFIED_BY="[Empty name]">
<P>We identified seven randomised controlled trials that generated eight publications.</P>
<P>All trials applied an intention-to-treat analysis with varied randomisation methods. The seven studies recruited 427 children and adolescents and no adults. We could not conduct a meta-analysis due to the heterogeneity of the studies.</P>
<P>Reported rates of seizure freedom reached as high as 55% in a 4 : 1 KD group after three months and reported rates of seizure reduction reached as high as 85% in a 4 : 1 KD group after three months.</P>
<P>One trial found no significant difference between the fasting-onset and gradual-onset KD for rates of seizure freedom and reported a greater rate of seizure reduction in the gradual-onset KD group.</P>
<P>Studies assessing the efficacy of the MAD reported seizure freedom rates of up to 10% and seizure reduction rates of up to 60%. One study compared the MAD to a 4 : 1 KD, but did not report rates of seizure freedom or seizure reduction.</P>
<P>Adverse effects were fairly consistent across different dietary interventions. The most commonly reported adverse effects were gastrointestinal syndromes. It was common that adverse effects were the reason for participants dropping out of trials. Other reasons for drop-out included lack of efficacy and non-acceptance of the diet.</P>
<P>Although there was some evidence for greater antiepileptic efficacy for a 4 : 1 KD over lower ratios, the 4 : 1 KD was consistently associated with more adverse effects.</P>
<P>No studies assessed the effect of dietary interventions on quality of life, or cognitive or behavioural functioning.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-01-07 11:42:48 +0000" MODIFIED_BY="[Empty name]">
<P>The randomised controlled trials discussed in this review show promising results for the use of KDs in epilepsy. However, the limited number of studies, small sample sizes and a sole paediatric population resulted in a poor overall quality of evidence.</P>
<P>There were adverse effects within all of the studies and for all KD variations, such as short-term gastrointestinal-related disturbances, to longer-term cardiovascular complications. Attrition rates remained a problem with all KDs and across all studies, reasons for this being lack of observed efficacy and dietary tolerance.</P>
<P>There was a lack of evidence to support the clinical use of KD in adults with epilepsy, therefore, further research would be of benefit.</P>
<P>Other more palatable but related diets, such as the MAD ketogenic diet, may have a similar effect on seizure control as classical KD but this assumption requires more investigation. For people who have medically intractable epilepsy or people who are not suitable for surgical intervention, a KD remains a valid option; however, further research is required.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-01-12 13:14:40 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-01-07 11:43:25 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-01-07 11:43:14 +0000" MODIFIED_BY="[Empty name]">
<P>Epilepsy is a common treatable neurological condition with a lifetime risk of 1% to 3% (<LINK REF="REF-Hauser-1990" TYPE="REFERENCE">Hauser 1990</LINK>). It is characterised by recurrent involuntary brain activity that manifests in seizures (<LINK REF="REF-Chang-2003" TYPE="REFERENCE">Chang 2003</LINK>). Although the majority of people with epilepsy will have a good response and become seizure free by treatment with antiepileptic drugs (AED), approximately 30% of people with epilepsy will continue to have seizures even when taking multiple AEDs (<LINK REF="REF-Granata-2009" TYPE="REFERENCE">Granata 2009</LINK>). Uncontrolled seizures pose a significant risk to quality of life (<LINK REF="REF-Lawn-2004" TYPE="REFERENCE">Lawn 2004</LINK>; <LINK REF="REF-Schmidt-2002" TYPE="REFERENCE">Schmidt 2002</LINK>; <LINK REF="REF-Villeneuve-2004" TYPE="REFERENCE">Villeneuve 2004</LINK>). In addition, uncontrolled tonic-clonic seizures are likely to be one of the strongest risk factors of sudden death in epilepsy (<LINK REF="REF-Nilsson-1999" TYPE="REFERENCE">Nilsson 1999</LINK>). Therefore, it is important not to rely on pharmacological interventions when treating refractory epilepsy and further evidence for alternative interventions must be developed.</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-01-07 11:43:20 +0000" MODIFIED_BY="[Empty name]">
<P>Diets have been used in an attempt to control epileptic seizures throughout the centuries, indeed there is a biblical reference to prayer and fasting in epilepsy (St Mark 9: 14-29). Scientific assessment of dietary manipulation reported in <LINK REF="REF-Guelpa-1911" TYPE="REFERENCE">Guelpa 1911</LINK>, and subsequently in <LINK REF="REF-Geyelin-1921" TYPE="REFERENCE">Geyelin 1921</LINK>, confirmed that seizures may cease on absolute fasting, but neither study was a randomised controlled trial (RCT). <LINK REF="REF-Wilder-1921" TYPE="REFERENCE">Wilder 1921</LINK> suggested that a diet high in fat and low in carbohydrates would be similar to fasting. The classical ketogenic diet (KD) uses a 4 : 1 ratio of total energy from fat to carbohydrate and protein. The KD has been described as unpalatable and difficult to tolerate, thus leading to poor compliance. Therefore, several diets have been investigated to improve palatability. The Atkins diet was initially used for weight reduction. It offers approximately a 1 : 1 ratio of energy from fat to carbohydrate and protein, through restricting carbohydrate to 10 g to 20 g per day (<LINK REF="REF-Atkins-1972" TYPE="REFERENCE">Atkins 1972</LINK>), and is considered less restrictive.</P>
<P>Prior to the introduction of anticonvulsant medications (<LINK REF="REF-Merritt-1938" TYPE="REFERENCE">Merritt 1938</LINK>), the KD was used in children (and adults) who were more representative of the current general population of people with epilepsy. However, case series published since the mid-1980s have generally included people with multiple seizure types refractory to multiple AEDs. The classic KD and other more palatable versions have a positive effect on infantile spasms, severe myoclonic epilepsy, tuberous sclerosis complex (<LINK REF="REF-Kossoff-2005" TYPE="REFERENCE">Kossoff 2005</LINK>), and children with refractory status epilepticus (<LINK REF="REF-O_x0027_Connor-2014" TYPE="REFERENCE">O'Connor 2014</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-01-07 11:43:21 +0000" MODIFIED_BY="[Empty name]">
<P>Although the anticonvulsant effects of the KD remain unclear, numerous biochemical theories have been suggested for the possible action of the diet. One theory suggests that the anticonvulsant effect of ketone bodies (acetoacetate, beta-hydroxybutyrate), ketone reduction of alanine efflux, charge of water and electrolyte imbalance (<LINK REF="REF-Schwartz-1989" TYPE="REFERENCE">Schwartz 1989</LINK>), results in changes occurring either in nerve cell lipid membranes or neurotransmitter production (<LINK REF="REF-Schwartz-1989" TYPE="REFERENCE">Schwartz 1989</LINK>; <LINK REF="REF-Schwartzkroin-1999" TYPE="REFERENCE">Schwartzkroin 1999</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-01-07 11:43:25 +0000" MODIFIED_BY="[Empty name]">
<P>Despite the use of the KD and other dietary treatments for adults and children with refractory epilepsy within clinical settings, the number of high-quality RCTs has been limited in recent years. Therefore, the evidence base for this intervention has been unclear. This review aims to assess the effectiveness of KDs and other dietary interventions when considering RCTs.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-01-07 11:43:25 +0000" MODIFIED_BY="[Empty name]">
<P>To review the evidence for efficacy and tolerability from randomised controlled trials regarding the effects of ketogenic and similar diets.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-01-07 11:44:48 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-01-07 11:43:32 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-01-07 11:43:26 +0000" MODIFIED_BY="[Empty name]">
<P>All RCTs or quasi-RCTs (using adequate methods of allocation concealment) of KD and other dietary interventions for people with epilepsy.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-01-07 11:43:27 +0000" MODIFIED_BY="[Empty name]">
<P>Adults and children with a diagnosis of epilepsy irrespective of their seizure type or epilepsy syndrome.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-01-07 11:43:30 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Ketogenic diet group (related diet)</HEADING>
<UL>
<LI>Any diet that is designed to produce ketones. There are several KDs that have been used depending upon the proportion of the different types of lipids. The two main types of diet are classical and medium-chain triglyceride (MCT); we also considered the modified Atkins diet (MAD).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control group</HEADING>
<UL>
<LI>Placebo/sham diet given as a control treatment that is thought to have no effect on epilepsy.</LI>
<LI>Any treatment with known antiepileptic properties.</LI>
</UL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-01-07 11:43:32 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-01-07 11:43:31 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Seizure freedom (100% reduction in seizure frequency).</LI>
<LI>Seizure reduction (50% or greater reduction in seizure frequency).</LI>
<LI>Adverse effects.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-01-07 11:43:32 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Cognitive and behaviour outcomes as measured by validated rating scales.</LI>
<LI>Quality of life as measured by validated rating scales.</LI>
<LI>Attrition rate.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-01-07 11:43:41 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2016-01-07 11:43:39 +0000" MODIFIED_BY="[Empty name]">
<P>For the most recent update of this review we searched:</P>
<UL>
<LI>the Cochrane Epilepsy Group Specialized Register (30 March 2015) using the search strategy outlined in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>;</LI>
<LI>the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 30 March 2015) using the search strategy outlined in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>;</LI>
<LI>MEDLINE (Ovid, 30 March 2015) using the search strategy outlined in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>;</LI>
<LI>
<A HREF="https://clinicaltrials.gov/">ClinicalTrials.gov</A> (30 March 2015) using the search terms: epilepsy AND diet;</LI>
<LI>the <A HREF="http://apps.who.int/trialsearch/">World Health Organization (WHO) International Clinical Trials Registry Platform</A> (ICTRP, 30 March 2015) using the search terms: epilepsy AND diet.</LI>
</UL>
<P>We searched EMBASE from 1980 to March 2003. We no longer have access to that database. However, RCTs and quasi-RCTs in EMBASE are included in CENTRAL. Therefore, these records are available to us via our searches of CENTRAL.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-01-07 11:43:41 +0000" MODIFIED_BY="[Empty name]">
<P>We searched references from previous versions of this review (backward referencing) and newer references from more up to date studies.</P>
<P>We contacted experts in the area to enquire about other relevant studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-01-07 11:44:48 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently selected all potential RCTs for eligibility according to criteria specified with data extracted from each publication. We resolved any disagreements by discussion. In addition to the main outcome measures listed above, for each study, we collected the following data using a pre-standardised data extraction form.</P>
<UL>
<LI>Participant characteristics including age, sex, number of participants (randomised to each group).</LI>
<LI>Diet intervention (classical, MCT, MAD or other).</LI>
<LI>Length of follow-up.</LI>
<LI>Epilepsy seizure type.</LI>
<LI>Reason for commencement.</LI>
<LI>Adverse effects.</LI>
<LI>Reason for drop-out including compliance.</LI>
</UL>
<P>We conducted an intention-to-treat (ITT) analysis where possible, including all allocated participants in the treatment groups to which they were allocated, irrespective of the treatment they received. Where necessary, we contacted original trial authors for additional data or clarification. We stratified results according to method of allocation concealment.</P>
<P>We assessed clinical heterogeneity by investigating the distribution of important prognostic factors between trials and assessed statistical heterogeneity using a Chi<SUP>2</SUP> test (P value &lt; 0.05). Provided we found no heterogeneity, we planned summary estimates across trials. Our preferred estimator was risk ratio with 95% confidence intervals (CIs) calculated using the Mantel-Haenszel method using both fixed-effect and random-effects models.</P>
<P>For behaviour, quality of life and cognitive outcomes, it was unlikely that individual authors would have addressed this in a uniform manner. In the first instance, we planned to summarise the results using text and tables.</P>
<STUDY_SELECTION MODIFIED="2016-01-07 11:43:56 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (CJ, KM) independently reviewed the titles and abstract of the studies identified by the electronic searches and removed studies that did not meet the inclusion criteria. The same two authors reviewed the full-text reports to determine eligibility. We resolved any disagreements by discussion. In the event of there being multiple reports deriving from one study, we linked the reports together. We produced a final list of studies to be included in the review.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-01-07 11:44:03 +0000" MODIFIED_BY="[Empty name]">
<P>In addition to the main outcome measures listed in <LINK TAG="CRIT_OUTCOMES_PRIMARY" TYPE="SECTION">Primary outcomes</LINK>; <LINK TAG="CRIT_OUTCOMES_SECONDARY" TYPE="SECTION">Secondary outcomes</LINK>, two review authors (CJ, KM) completed data extraction for each study. We cross-checked results of the data extraction and resolved any disagreements by discussion.</P>
<P>We collected the following data using a pre-standardised data extraction form.</P>
<UL>
<LI>Participant characteristics including age, sex and number of participants (randomised to each group).</LI>
<LI>Diet intervention (classical or MCT or other).</LI>
<LI>Length of follow-up.</LI>
<LI>Epilepsy seizure type.</LI>
<LI>Reason for commencement.</LI>
<LI>Adverse effects.</LI>
<LI>Reason for drop-out including compliance.</LI>
</UL>
<P>We conducted an ITT analysis where possible, including all allocated participants in the treatment groups to which they were allocated, irrespective of the treatment they received. Where necessary, we contacted original trial authors for additional data or clarification.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-01-07 11:44:11 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (CJ, KM) independently assessed the risk of bias and compared the results from these assessments to identify any inconsistencies. We resolved any disagreements by discussion.</P>
<P>We assessed all domains of the current Cochrane tool for assessing risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We presented an overall summary judgement of risk of bias for each outcome per study and made an overall risk of bias assessment for each outcome across all studies.</P>
<P>Where possible, we planned to incorporate the risk of bias judgement into the analysis using sensitivity analysis. This analysis of the data would have included only studies rated as low risk of bias. We created a 'Summary of findings' table for outcomes, and graded each outcome using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-01-07 11:44:16 +0000" MODIFIED_BY="[Empty name]">
<P>Where possible, we presented outcomes as RRs with 95% CI and reported secondary outcomes narratively.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-01-07 11:44:18 +0000" MODIFIED_BY="[Empty name]">
<P>In the event of unit of analysis issues being identified across studies (e.g. cross-over, cluster randomised or repeated measures studies), we planned to:</P>
<UL>
<LI>determine whether the methods in such studies were conducted appropriately;</LI>
<LI>combine extracted effect sizes from such studies through a generic inverse variance meta-analysis.</LI>
</UL>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-01-07 11:44:19 +0000" MODIFIED_BY="[Empty name]">
<P>In the event of missing data, we planned to contact study authors for the data or to determine if data were missing at random or not.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-01-07 11:44:29 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors assessed clinical and methodological heterogeneity by investigating the distribution of important prognostic factors between trials and the study design. We assessed statistical heterogeneity using a Chi<SUP>2</SUP> test (P value &lt; 0.05) and an I<SUP>2</SUP> statistic of greater than 50% to indicate statistical heterogeneity in accordance with Cochrane guidelines (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>Provided we found no heterogeneity, we planned summary estimates across trials. Our preferred estimator was RRs with 95% CIs calculated using the Mantel-Haenszel method using both fixed-effect and random-effects models.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-01-07 11:44:32 +0000" MODIFIED_BY="[Empty name]">
<P>We investigated outcome reporting bias using the ORBIT matrix system (<LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>). We requested all protocols from study authors to compare outcomes of interest.</P>
<P>To examine publication bias, We identified any unpublished data by carrying out a comprehensive search of multiple sources and requesting unpublished data from study authors. We planned to examine funnel plots in the event of there being 10 or more studies that could be combined, in accordance with Cochrane recommendations (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-01-07 11:44:40 +0000" MODIFIED_BY="[Empty name]">
<P>Ideally, we would have presented the data in a fixed-effect meta-analysis; however, as we expected some heterogeneity across the studies, we carried out a random-effects meta-analysis.</P>
<P>We planned to present seizure freedom, seizure reduction by 50% and adverse effects as RRs with 95% CIs.</P>
<P>Due to significant clinical and methodological heterogeneity, meta-analysis was not possible and, therefore, we reported the outcomes narratively.</P>
<P>We planned to carry out the following comparisons:</P>
<UL>
<LI>KD compared with a control;</LI>
<LI>KD compared with other dietary interventions;</LI>
<LI>KD compared with other interventions;</LI>
<LI>other dietary interventions compared with a control;</LI>
<LI>other dietary interventions compared with other interventions.</LI>
</UL>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-01-07 11:44:41 +0000" MODIFIED_BY="[Empty name]">
<P>We planned to stratify comparisons by control group, participant group, study characteristics, or a combination of these to ensure appropriate combination of study data.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-01-07 11:44:48 +0000" MODIFIED_BY="[Empty name]">
<P>We intended to carry out sensitivity analysis if we found peculiarities between study quality. We planned to report and compare analyses for all studies only of studies at low risk of bias.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-01-12 13:14:36 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-01-07 11:45:26 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2016-01-07 11:44:58 +0000" MODIFIED_BY="[Empty name]">
<P>Previous versions of this review identified four RCTs (<LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK>; <LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK>; <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK>; <LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK>).</P>
<P>The search strategies were updated and, therefore, there were no date restrictions placed on the updated searches.</P>
<P>The updated search revealed 230 studies from the databases outlined in <LINK TAG="ELECTRONIC_SEARCHES" TYPE="SECTION">Electronic searches</LINK> and three additional studies through other sources. After removing duplicates, 156 studies remained. Initial screening removed 143 irrelevant studies leaving 13 studies. The remaining studies underwent full-text review after which we excluded a further four studies (<LINK REF="STD-Freeman-1999" TYPE="STUDY">Freeman 1999</LINK>; <LINK REF="STD-Freeman-2009" TYPE="STUDY">Freeman 2009</LINK>; <LINK REF="STD-Hemingway-2001" TYPE="STUDY">Hemingway 2001</LINK>; <LINK REF="STD-Smith-2011" TYPE="STUDY">Smith 2011</LINK>), identified two studies as ongoing (<LINK REF="STD-Hulshof-2014" TYPE="STUDY">Hulshof 2014</LINK>; <LINK REF="STD-Yoon-2014" TYPE="STUDY">Yoon 2014</LINK>), and deemed seven studies eligible for inclusion in the present review update. Four of the identified studies were included in previous versions of this review (<LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK>; <LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK>; <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK>; <LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK>), therefore we included three new RCTs in this update (<LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK>; <LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>).</P>
<P>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> shows the search results from the present update.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-01-07 11:45:19 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Bergqvist 2005 (USA)</HEADING>
<P>
<LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK> was a prospective, randomised, single-centre study of 48 participants aged one to 14 years (mean 5.3, standard deviation (SD) 2.7) comparing fasting and gradual-onset KD over a three-month period. Participants were recruited from The Children's Hospital of Philadelphia and randomised into two groups of equal numbers using permuted blocks of random size. Participants were stratified by age, one to two years and two to 14 years to aid equal allocation. Baseline data of seizure activity was collected 28 days prior to diet initiation. There was no significant difference in participant demographics between the groups. Inclusion criteria applied were children aged one to 14 years, having one or more seizures per 28 days, tried at least three antiepileptic medications and a discontinuation of steroidal medication three months previous. Exclusion criteria applied to children with metabolic disorders, genetic disorders and known or suspected neurodegenerative disorders. Forty-two percent of children included in the study had cerebral palsy. The study aimed to compare the efficacy of fasting KD to gradual initiation KD. Primary outcome was seizure reduction and secondary outcomes were ketosis and adverse effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">El-Rashidy 2013 (Egypt)</HEADING>
<P>
<LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK> was a single-centre RCT of 40 participants aged 12 to 36 months (mean 27.13, SD 6.63) to compare two different dietary interventions and a control group. Participants were recruited from the Paediatric Neurology Outpatient Clinic at Children's Hospital Ain Shams University and were randomised into one of three groups; MAD (15 children), classic ketogenic (4 : 1) liquid diet (10 children) and a control (polytherapy) (15 children). There was no significant difference in age or gender across the groups. The trial excluded children under the age of one year diagnosed with idiopathic epilepsy or with other systemic chronic conditions. Two children in the classic group had infantile spasms and one child in the classic group had myoclonic encephalopathy. Aims of the study were to assess efficacy and tolerability. Outcomes reported were changes in seizure frequency at three and six months, adverse effects and attrition rates.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Kossoff 2007 (USA)</HEADING>
<P>
<LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK> was a prospective, randomised, cross-over controlled trial of 20 participants aged three to 18 years comparing daily carbohydrate limits of 10 g and 20 g, using MAD. Participants were recruited from the John Hopkins Hospital outpatient paediatric epilepsy clinic and randomised into two groups, 10 g carbohydrate MAD (10 children) or 20 g carbohydrate MAD (10 children), which was followed for a three-month period. After this time, participants were crossed over into the other group and followed for a further three months. A return to the previous carbohydrate amount was permitted after two weeks if parents deemed seizure control to be worse. There was no significant difference in participant demographics between the groups. Inclusion criteria were aged three to 18 years, prior use of at least two anticonvulsants and daily seizures. Epilepsy syndromes included were idiopathic (15 children), Rett syndrome (two children), cortical dysplasia (two children) and tuberous sclerosis complex (one child). Exclusion criteria included children with prior experience of the diet for more than seven days, hypercholesterolaemia, kidney dysfunction, body mass index less than 3% for age and children with heart disease. The study aimed to investigate the ideal starting value of carbohydrate in the MAD. Primary outcome was seizure control and secondary outcomes were ketosis and tolerability.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Neal 2008 (UK)</HEADING>
<P>
<LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK> was a prospective, randomised, non-blinded, controlled trial of 145 participants aged two to 16 years comparing KD (classic and MCT combined) to controls over a three-month period, with a follow-on study that compared classic KD versus MCT KD over a 12-month period. Most participants were recruited from Great Ormond Street Hospital for Children, with a few participants seen in Central Middlesex Hospital and a residential centre (National Centre for Young People with Epilepsy). Participants were randomised, using a computer package, to commence a diet (classic or MCT) after a four-week baseline or after baseline and a further three months of seizure recording, with the latter group acting as the control. The study used three defined age groups to aid the randomisation between groups (two to six years, seven to 11 years and 12 to 16 years). Participant demographics were well matched between the groups. Inclusion criteria were children aged two to 16 years, with daily seizures and more than seven seizures per week, who had not responded to two or more AEDs who had not previously been treated with a KD. Exclusion criteria included hyperlipidaemia, renal stones or organic acid deficiency syndromes. Fourteen participants had Lennox-Gastaut syndrome and 11 had West syndrome. The study aimed to investigate the efficacy of the KD in comparison to a control and to compare classic KD versus MCT KD for efficacy and tolerability at three, six and 12 months. The primary outcome was efficacy, with the secondary outcome of tolerability (assessed via a questionnaire at three, six and 12 months).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Raju 2011 (India)</HEADING>
<P>
<LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK> was a randomised, non-blinded, open-label, parallel controlled trial of children aged six months to five years, with refractory epilepsy comparing a 4 : 1 and a 2.5 : 1 ratio KD. Participants were recruited from a single centre, paediatric department of a tertiary care hospital in India. Participants were randomised using a computer-generated random number table and concealment was undertaken using opaque envelopes. Thirty-eight participants were recruited, 19 received a 4 : 1 ratio KD and 19 received a 2.5 : 1 KD, with outcomes being assessed three months after dietary initiation. There were no significant differences between participant demographics at baseline. Epilepsy syndromes included were West syndrome (nine participants in 4 : 1 KD group and seven participants in 2.5 : 1 KD group), Lennox-Gastaut syndrome (eight participants in 4 : 1 KD group and nine participants in 2.5 : 1 KD group), Doose (no participants in 4 : 1 KD group and two participants in 2.5 : 1 KD group) and unclassified syndromes (two participants in 4 : 1 KD group and one participant in 2.5 : 1 KD group). Trial included participants with cerebral palsy (15 participants in 4 : 1 KD group and nine participants in 2.5 : 1 KD group). Inclusion criteria were children aged six months to five years, at least two seizures per months, despite appropriate use of at least two AED and at least one newer AED. Exclusion criteria were known or suspected inborn errors of metabolism, systemic illness or surgical remediable causes of epilepsy. Aims of the study were to compare the efficacy and tolerability of 2.5 : 1 KD versus 4 : 1 KD. Primary outcome was the proportion of participants with more than 50% reduction in seizure frequency in both groups and secondary outcome was adverse effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Seo 2007 (Korea)</HEADING>
<P>
<LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK> was a single-centre RCT of 76 children with intractable childhood epilepsy aged four months to 16 years comparing 3 : 1 KD and 4 : 1 KD. Participants were recruited from a paediatric epilepsy clinic in Severance Children's Hospital and were randomised into two groups, 4 : 1 KD group (40 participants) and 3 : 1 KD group (36 participants) and the diet was followed for three months. A baseline seizure frequency monitoring period was completed two months prior to commencement of KD. After a three-month period of the diet, children who were seizure free in the 4 : 1 group were recommended to change to a 3 : 1 ratio, and children who were not seizure free in the 3 : 1 group were recommended to change to a 4 : 1 ratio and re-evaluated after a further three months. There were no significant differences in participant demographics between the groups. Epilepsy syndromes included Lennox-Gastaut syndrome and study also included participants with infantile spasm. Inclusion criteria were more than four seizures per months and seizures were not controlled by at least three AEDs. Exclusion criteria were children with metabolic disorders or known or suspected neurological degenerative disorders (or both). The study aimed to compare the antiepileptic efficacy and diet tolerability of 3 : 1 and 4 : 1 KDs. Primary outcome was a reduction in seizure activity from baseline and secondary outcome was to assess tolerability.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sharma 2013 (India)</HEADING>
<P>
<LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK> was an open-label, parallel-group, RCT of children aged two to 14 years with refractory epilepsy comparing the MAD to a control group. This was conducted in a single, tertiary care centre. Authors noted the study design to be similar to that of <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK>. Participants were randomised into an intervention (MAD) or a control (normal diet) arm using computer-generated random number tables. Concealment was carried out using opaque sealed envelopes. There were 102 participants, 50 received MAD and 52 received a normal diet for a period of three months. There were no significant differences in participant demographics across the two groups. Epilepsy syndromes included Lennox-Gastaut syndrome (25 participants in MAD group and 22 participants in control group), West syndrome (nine participants in MAD group and 10 participants in control group) and myoclonic astatic epilepsy (two participants in MAD group and three participants in control group). Other inclusion criteria were two to 14 daily seizures and previous tried three AEDs. Exclusion criteria were known or suspected inborn errors of metabolism, systemic illness or motivational issues of the family that would prelude compliance. Seizure frequency was recorded for a four-week baseline period and repeated at the end of the three-month study period. Aim of the study was to evaluate the efficacy of the MAD. Outcomes reported were seizure frequency, tolerability and adverse effects.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-01-07 11:45:26 +0000" MODIFIED_BY="[Empty name]">
<P>The present update excluded four studies at full-text review. Three studies were not RCTs (<LINK REF="STD-Freeman-1999" TYPE="STUDY">Freeman 1999</LINK>; <LINK REF="STD-Hemingway-2001" TYPE="STUDY">Hemingway 2001</LINK>; <LINK REF="STD-Smith-2011" TYPE="STUDY">Smith 2011</LINK>), and one study was successfully blinded after fasting (by administration of saccharin or glucose) (<LINK REF="STD-Freeman-2009" TYPE="STUDY">Freeman 2009</LINK>); however, <LINK REF="STD-Freeman-2009" TYPE="STUDY">Freeman 2009</LINK> was only for 12 days and ketosis was not completely eliminated in the glucose arm).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-01-07 11:45:54 +0000" MODIFIED_BY="[Empty name]">
<P>There were seven RCTs that generated eight publications reviewing the use of ketogenic and other diets appropriate for analysis of bias. For further details please refer to <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<ALLOCATION MODIFIED="2016-01-07 11:45:26 +0000" MODIFIED_BY="[Empty name]">
<P>Three studies used a computer-generated method of sequence generation and allocation concealment (<LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK>; <LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>), and one study used a permuted block randomisation method (<LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK>). We rated these studies at low risk of allocation bias.</P>
<P>The method of sequence generation and allocation concealment was unclear in three studies (<LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK>; <LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK>; <LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-01-07 11:45:26 +0000" MODIFIED_BY="[Empty name]">
<P>We rated all studies at high risk of performance bias and detection bias. This may be due to the design of such studies, in that blinding participants and study personnel did not occur.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-01-07 11:45:26 +0000" MODIFIED_BY="[Empty name]">
<P>Two studies reported comparable drop-out rates across the groups but did not complete an ITT analysis (<LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK>; <LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK>). Three studies also reported comparable drop-out rates across the groups and completed an ITT analysis (<LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK>; <LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>). We rated these studies at low risk of attrition bias.</P>
<P>One study reported a high level of participants in the control group being lost to follow-up (<LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK>), and one study reported uneven drop-out rates across the groups and did not complete an ITT analysis (<LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK>). We rated these studies at high risk of attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-01-07 11:45:26 +0000" MODIFIED_BY="[Empty name]">
<P>We contacted the authors of all included studies to request protocols. Two study authors provided the protocol for the included studies and on reviewing the outcomes, there was no evidence to suggest selective reporting for either study (<LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK>; <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK>). Therefore, we rated these studies at low risk of bias. Protocols for the remaining five studies were unavailable and we rated these studies at unclear risk of selection bias (<LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK>; <LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK>; <LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK>; <LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-01-07 11:45:54 +0000" MODIFIED_BY="[Empty name]">
<P>One study reported that three participants in one of the intervention group had other conditions; two had been diagnosed with infantile spasms and one with myoclonic encephalopathy (<LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK>). One study reported a high level of co-morbidity among all groups and although they were comparable within this study, this may introduce bias when evaluating in a meta-analysis (<LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK>). One study excluded children where motivational issues within the family that may impact on compliance had been identified (<LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>). We rated these studies at high risk of bias.</P>
<P>There were no other sources of bias identified in four studies (<LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK>; <LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK>; <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK>; <LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-01-12 13:14:36 +0000" MODIFIED_BY="[Empty name]">
<P>All outcomes are presented in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and are described in more detail below.</P>
<SUBSECTION>
<HEADING LEVEL="3">Seizure freedom (100% reduction in seizure frequency)</HEADING>
<P>
<LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK> reported 26% (5/19) of participants following a 4 : 1 KD and 21% (4/19) of participants following a 2.5 : 1 KD to be seizure free at three months. <LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK> found a greater response rate to both ratios of the KD, reporting 55% (22/40) of participants to be seizure free after following a 4 : 1 KD for three months compared to 35% (11/36) of participants following a 3 : 1 KD. <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK> reported one participant to be seizure free after three months of following a KD (classic and MCT). When comparing a fasting-onset and a gradual-onset KD, <LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK> stated 21% (5/24) of participants of both fasting-onset and gradual-onset KD groups were seizure free at three months. For the MAD, <LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK> reported 10% (2/20) of participants to be seizure free by six months. However, the intervention group (10 g or 20 g carbohydrate per day via MAD) was not stated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Seizure reduction (50% or greater reduction in seizure frequency)</HEADING>
<P>
<LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK> found the number of participants with greater than 50% seizure reduction after three months to be 58% (11/19) in the 4 : 1 KD group and 63% (12/19) in the 2.5 : 1 KD group; however, there was no significant difference. <LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK> stated 85% (34/40) of participants following a 4 : 1 KD and 72.2% (26/36) of participants following a 3 : 1 KD to have greater than 50% seizure reduction after three months. <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK> reported 38% (28/73) of participants had greater than 50% seizure reduction after three months in the KD (classic and MCT) group compared to 6% (4/72) of participants in the control group (P value &lt; 0.0001). When comparing fasting-onset and gradual-onset KD, <LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK> found 58% (14/24) of participants in the fasting-onset KD and 67% (16/24) of participants in the gradual-onset KD group to have greater than 50% seizure reduction at three months.</P>
<P>When investigating the effects of MAD on seizure reduction, <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK> reported significantly higher results in the MAD group (52%) to the control (11.5%, P value = 0.001), when comparing greater than 50% seizure reduction at three months. <LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK> reported a significant difference (P value = 0.03) in seizure reduction after three months, between 10 g carbohydrate MAD and 20 g carbohydrate MAD, with 60% (6/10) of participants in the 10 g carbohydrate/day group having greater than 50% seizure reduction compared to 10% (1/10) of participants in the 20 g carbohydrate/day group.</P>
<P>
<LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK> reported that antiepileptic efficacy was significantly greater in the 4 : 1 KD group than the 3 : 1 KD group (P value = 0.041), but it was unclear as to whether this referred to seizure reduction, seizure freedom or both.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>All studies reported adverse effects of the dietary interventions. For those studies investigating the classical KD , the main adverse effects were gastrointestinal symptoms, including vomiting, constipation and diarrhoea (<LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK>; <LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK>; <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK>; <LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK>; <LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK>). <LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK> found gastrointestinal symptoms to be significantly worse in the 4 : 1 ratio compared with the 3 : 1 ratio KD (P value = 0.038), while <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK> reported vomiting to significantly affect more participants in the classical KD (45%) compared with the MCT KD group (13%, P value &lt; 0.05). Weight loss was reported upon by two KD studies (<LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK>; <LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK>). <LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK> found weight loss to affect more participants (3/19) in the 4 : 1 ratio KD group than in the 2.5 : 1 (1/19) ratio KD group. <LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK> found gradual-onset KD participants lost significantly less weight than the fasting-onset KD group; -0.95 kg (95% CI -2.9 to 0.6) with fasting-onset KD compared to -0.3 kg (95% CI -2.1 to 1.5) with gradual-onset KD; P value = 0.006. <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK> also reported statistical significance with regards to a lack of energy at three months, affecting 36% of participants in the classical KD group compared to 14% of participants in the MCT group (P value &lt; 0.05). Other adverse effects reported by the studies in lower numbers were respiratory tract infection, infectious disease (pneumonia and sepsis), acute pancreatitis, decreased bone matrix density, gallstones, fatty liver, nephrocalcinosis, hypercholesterolaemia, status epilepticus, acidosis, dehydration, tachycardia, extended hospital stay, hunger and abdominal pain.</P>
<P>Adverse effects were also reported in the MAD trials (<LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK>; <LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>). All three studies reported constipation to affect the dietary intervention groups, with 20% to 46% of participants affected. <LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK> reported constipation to affect 15.4% of participants in the MAD group and 25% of participants in the classic group, but no significance was reported. <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK> and <LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK> reported vomiting to affect 10% of participants in the MAD group and 30% of participants in the classic group. <LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK> also reported diarrhoea to affect more of the MAD participants than the classic KD participants (15.4% in the MAD group, 12.5% in the classic group). <LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK> found no significant difference between median weight change in the 10 g and 20 g carbohydrate MAD groups in the first three months (P value = 0.44). Other adverse effects were anorexia, lethargy, lower respiratory tract infections and hyperammonaemic encephalopathy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cognitive and behaviour outcomes</HEADING>
<P>We found no RCTs into the effects of a KD or similar diets on psychosocial impact.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>We found no RCTs into the effects of a KD or similar diets on quality of life.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Attrition rate</HEADING>
<P>All trials experienced drop-outs.</P>
<P>In the studies investigating classic KD, drop-outs ranged from 10% to 20% (<LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK>; <LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK>; <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK>; <LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK>; <LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK>). Reasons for drop-out included lack of efficacy, refusal to eat, non-acceptance of diet by other family members, along with medical conditions including acute pancreatitis, viral gastrointestinal illness, respiratory distress and increased seizure activity.</P>
<P>In the studies investigating the MAD, drop-out rates were between 8% and 50% (<LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK>; <LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK>; <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK>). Reasons for drop-out reported by <LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK> and <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK> were non-acceptance of the diet and weight loss, along with medical conditions including lower respiratory tract infections and hyperammonaemic encephalopathy. <LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK> did not report reasons for drop-outs; however, they found no significant difference between 10 g and 20 g carbohydrate MAD drop-out rates (P value = 0.33).</P>
<P>For further details, refer to <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-01-07 11:46:19 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-01-07 11:46:14 +0000" MODIFIED_BY="[Empty name]">
<P>The present update identified three additional RCTs and, therefore, this review includes seven RCTs. All of the studies assessed the efficacy of various dietary interventions for children with epilepsy.</P>
<P>The review presented some promising, although limited, evidence for the use of KDs in epilepsy. Reported rates of seizure freedom reached 55% in a 4 : 1 KD group after three months and reported rates of seizure reduction reached 85% in a 4 : 1 KD group after three months (<LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK>).</P>
<P>Interestingly, <LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK> found no significant difference between the fasting-onset and gradual-onset KD for rates of seizure freedom and reported a greater rate of seizure reduction in the gradual-onset KD group.</P>
<P>Studies assessing the efficacy of the MAD reported seizure freedom rates of up to 10% and seizure reduction rates of up to 60%. One study compared the MAD to a 4 : 1 KD, but did not report rates of seizure freedom or seizure reduction (<LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK>).</P>
<P>Adverse effects were fairly consistent across different dietary interventions. The most commonly reported adverse effects were gastrointestinal syndromes. It was common that adverse effects were the reason for participants dropping out of trials. Other reasons for drop-out included lack of efficacy and non-acceptance of the diet.</P>
<P>Although there was some evidence for greater antiepileptic efficacy for a 4 : 1 KD over lower ratios, the 4 : 1 LD was consistently associated with more adverse effects.</P>
<P>No studies assessed the effect of dietary interventions of quality of life, cognitive or behavioural functioning.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-01-07 11:46:14 +0000" MODIFIED_BY="[Empty name]">
<P>The present review identified only seven RCTs with a total sample size of 427 children with epilepsy. Due to the clinical, methodological heterogeneity, meta-analysis was not possible for this review. This demonstrates the limitations of the evidence for dietary interventions in people with epilepsy. Furthermore, there is a lack of consensus regarding which dietary intervention is most effective and appropriate. This highlights the need for further research in this area to address these issues.</P>
<P>All of the included studies assessed the efficacy of dietary interventions in children. However, the evidence for the use of dietary interventions in adults with epilepsy appears to be anecdotal. Therefore, further research is required to provide high-quality evidence for the use of dietary interventions in adults, in addition to expanding on evidence in paediatric populations.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-01-07 11:46:14 +0000" MODIFIED_BY="[Empty name]">
<P>The quality of the evidence was low. This is due to the relatively small sample size and high risk of bias in the included studies. In addition, two of the included studies reported a high incidence of co-morbidity (<LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK>; <LINK REF="STD-El_x002d_Rashidy-2013" TYPE="STUDY">El-Rashidy 2013</LINK>).</P>
<P>There was considerable heterogeneity across the included studies in terms of the clinical populations, interventions and methodologies. Therefore, combined data from included studies was problematic and meta-analysis was not possible in this review. This is a limitation of this study and impacts on the quality of evidence presented.</P>
<P>For further details please refer to <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-01-07 11:46:19 +0000" MODIFIED_BY="[Empty name]">
<P>Despite the thorough search strategies, we cannot be certain that we identified and included all relevant data in this review. Should further data be identified following publication of this review, it will be incorporated into subsequent updates.</P>
<P>There was limited information about the included studies, in particular study protocols were unavailable for the majority of included studies, therefore decisions within the risk of bias assessment were often based on insufficient information, resulting in a number of unclear risk of bias judgements.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-01-07 11:46:19 +0000" MODIFIED_BY="[Empty name]">
<P>We found two prospective studies investigating the effect of KD on epilepsy in an adult population (<LINK REF="REF-Kossoff-2008" TYPE="REFERENCE">Kossoff 2008</LINK>; <LINK REF="REF-Moesk-2009" TYPE="REFERENCE">Moesk 2009</LINK>). <LINK REF="REF-Kossoff-2008" TYPE="REFERENCE">Kossoff 2008</LINK> investigated the effects of a MAD (30 participants), while <LINK REF="REF-Moesk-2009" TYPE="REFERENCE">Moesk 2009</LINK> used a classic 4 : 1 KD (nine participants). Drop-out rates varied between 30% and 77%, reportedly due feeling of hunger, dietary restrictions and lack of efficacy. <LINK REF="REF-Moesk-2009" TYPE="REFERENCE">Moesk 2009</LINK> reported that both of the participants who completed the study had greater than 50% seizure reduction by three months, while <LINK REF="REF-Kossoff-2008" TYPE="REFERENCE">Kossoff 2008</LINK> reported that 47% of participants had experienced this level of seizure reduction. Both studies reported an increase in cholesterol levels. The findings of <LINK REF="REF-Kossoff-2008" TYPE="REFERENCE">Kossoff 2008</LINK> were similar to those of the included RCTs discussed above, which may demonstrate the ability for adults to achieve a similar level of seizure reduction as that of children. However, attrition rates experienced by <LINK REF="REF-Moesk-2009" TYPE="REFERENCE">Moesk 2009</LINK> were considerably higher than the RCTs conducted on children, which may suggest tolerability of a 4 : 1 KD or lack of efficacy to be problematic in the adult population.</P>
<P>Further prospective studies with children reported similar levels of seizure reduction to those of the included RCTs (<LINK REF="REF-Coppola-2002" TYPE="REFERENCE">Coppola 2002</LINK>; <LINK REF="REF-Hosain-2005" TYPE="REFERENCE">Hosain 2005</LINK>). <LINK REF="REF-Hosain-2005" TYPE="REFERENCE">Hosain 2005</LINK> administered a KD via gastrostomy tubes and reported compliance rates of 100% (12 children), likely due to the method of delivery.</P>
<P>Retrospective studies found 58% (<LINK REF="REF-Kang-2005" TYPE="REFERENCE">Kang 2005</LINK>) and 35% (<LINK REF="REF-DiMario-2002" TYPE="REFERENCE">DiMario 2002</LINK>) of children to have greater than 50% seizure reduction following six months of KD. However, given the time scale, direct comparison of results are difficult. Adverse effects in both studies were mild and self limited. <LINK REF="REF-Kang-2005" TYPE="REFERENCE">Kang 2005</LINK> reported a 32% drop-out rate, which is slightly greater than the included RCTs, reportedly due to complications and dietary intolerances. However, four participants were also reported to had died during the study, three due to lipoid pneumonia and infectious illnesses that occurred within three months of starting a KD.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-01-07 11:46:23 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-01-07 11:46:23 +0000" MODIFIED_BY="[Empty name]">
<P>The randomised controlled trials (RCTs) discussed in this review show promising results for the use of ketogenic diets (KD) in epilepsy. However, the limited number of studies, small sample sizes and a sole paediatric population result in a poor overall quality of evidence.</P>
<P>All studies comparing all KD variations reported adverse effects, from short-term gastrointestinal-related disturbances, to longer-term cardiovascular complications. The adverse effects associated with the modified Atkins KDs may initially appear lower than the classic KD, but we found no significant results.</P>
<P>Attrition rates remained a problem in all KDs and across all studies, reasons for this being lack of observed efficacy and dietary tolerance.</P>
<P>One study found no significant difference in seizure reduction between gradual-onset and fasting-onset KD, which could prove cost effective and time saving. However, further large-scale studies are required.</P>
<P>There was a lack of evidence to support the clinical use of KD in adults with epilepsy, therefore, further research would be of benefit.</P>
<P>Other more palatable but related diets, such as the modified Atkins KD, may have a similar effect on seizure control as classical KD but this assumption requires more investigation.</P>
<P>For people who have medically intractable epilepsy or people who are not suitable for surgical intervention, a KD remains a valid option; however, further research is required.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-01-07 11:46:23 +0000" MODIFIED_BY="[Empty name]">
<P>Key areas for research identified by this review are as follows:</P>
<UL>
<LI>studies should address quality of life issues and cognitive changes using a validated scale;</LI>
<LI>consistency in outcomes across RCTs would be beneficial to research as a limitation of the present review was that meta-analysis was not possible. It may be beneficial for future RCTs to assess seizure frequency by means of seizure reduction (greater than 50% reduction in seizures) and seizure freedom (100% reduction in seizures);</LI>
<LI>although shorter studies (e.g. six months) provide useful evidence for the efficacy of dietary interventions, it may be useful to assess the tolerability and adverse effects of such interventions in long-term studies that follow participants for over 12 months or preferably several years;</LI>
<LI>studies of the mechanisms of action could help determine which specific seizure types or syndromes respond better to the diets;</LI>
<LI>further studies should address other diets, particularly those that are less restrictive (such as the modified Atkins);</LI>
<LI>the present review highlighted a paucity of evidence for the use of the KD in adults. Therefore, future studies should investigate the use and potential adverse effects of KDs, in adults with epilepsy;</LI>
<LI>large-scale RCTs would be of benefit.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-02-03 15:51:09 +0000" MODIFIED_BY="[Empty name]">
<P>We would like to thank Pratima Giri and Jennifer Weston for contributions to previous versions of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-01-20 14:58:14 +0000" MODIFIED_BY="[Empty name]">
<P>KM: none known</P>
<P>CJ: none known</P>
<P>RL: none known</P>
<P>PC: none known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-01-20 14:57:31 +0000" MODIFIED_BY="[Empty name]">
<P>Kirsty Martin was responsible for the update of this review.</P>
<P>Cerian F Jackson provided support for the update of this review.</P>
<P>Robert Levy provided expert opinion and feedback.</P>
<P>Paul Cooper provided expert opinion and feedback.</P>
<P>Pratima Giri contributed to previous versions.</P>
<P>Jennifer Weston contributed to previous versions.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-01-07 11:46:32 +0000" MODIFIED_BY="[Empty name]">
<P>The background and method sections have been updated in accordance with changes to Cochrane requirements.</P>
<P>Searching other results now states that forward and backward referencing will be completed on included studies and experts in the area will be contacted.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2010-11-23 11:55:02 +0000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-02-03 15:45:58 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2016-02-03 15:45:58 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-02-03 15:45:58 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bergqvist-2005" MODIFIED="2015-07-29 11:51:21 +0100" MODIFIED_BY="[Empty name]" NAME="Bergqvist 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-07-29 11:51:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergqvist AGC, Schall JI, Gallagher PR, Cnaan A, Stallings VA</AU>
<TI>Fasting versus gradual initiation of the ketogenic diet: a prospective, randomized clinical trial of efficacy</TI>
<SO>Epilepsia</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>11</NO>
<PG>1810-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Rashidy-2013" MODIFIED="2016-01-07 11:50:37 +0000" MODIFIED_BY="[Empty name]" NAME="El-Rashidy 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-01-07 11:50:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Rashidy OF, Nassar MF, Abde-Hamid IA, Shatla RH, Abdel-Hamid HM, Gabr SS, et al</AU>
<TI>Modified Atkins diet vs classic ketogenic formula in intractable epilepsy</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2013</YR>
<VL>128</VL>
<NO>6</NO>
<PG>402-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kossoff-2007" MODIFIED="2015-01-27 14:11:27 +0000" MODIFIED_BY="[Empty name]" NAME="Kossoff 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-01-27 14:11:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kossoff EH, Turner Z, Bluml RM, Pyzik PL, Vining EPG</AU>
<TI>A randomized, crossover comparison of daily carbohydrate limits using the modified Atkins diet</TI>
<SO>Epilepsy &amp; Behavior</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>3</NO>
<PG>432-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-10-19 16:02:45 +0100" MODIFIED_BY="Pratima Giri"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neal-2008" MODIFIED="2016-01-07 12:38:22 +0000" MODIFIED_BY="[Empty name]" NAME="Neal 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-01-07 11:50:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, et al</AU>
<TI>A randomised trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy</TI>
<SO>Epilepsia</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>5</NO>
<PG>1109-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2016-01-07 12:38:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, et al</AU>
<TI>The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial</TI>
<SO>Lancet Neurology</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>6</NO>
<PG>500-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-10-19 13:09:48 +0100" MODIFIED_BY="Pratima Giri"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raju-2011" MODIFIED="2016-01-07 11:50:51 +0000" MODIFIED_BY="[Empty name]" NAME="Raju 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-01-07 11:50:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raju KNV, Gulati S, Kabra M, Agarwala A, Sharma S, Pandey RM, et al</AU>
<TI>Efficacy of 4:1 (classic) versus 2.5:1 ketogenic ratio diets in refractory epilepsy in young children: a randomized open labeled study</TI>
<SO>Epilepsy Research</SO>
<YR>2011</YR>
<VL>96</VL>
<NO>(1-2)</NO>
<PG>96-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seo-2007" MODIFIED="2016-02-03 15:45:58 +0000" MODIFIED_BY="[Empty name]" NAME="Seo 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-02-03 15:45:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seo JH, Lee YM, Lee JS, Kang HC, Kim HC</AU>
<TI>Efficacy and tolerability of the ketogenic diet according to lipid: nonlipid ratios - comparison of 3:1 with 4:1 diet</TI>
<SO>Epilepsia</SO>
<YR>2007</YR>
<VL>48</VL>
<NO>4</NO>
<PG>801-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2013" MODIFIED="2015-07-29 13:54:34 +0100" MODIFIED_BY="[Empty name]" NAME="Sharma 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-07-29 13:54:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma S, Sankhyan N, Gulati S, Agarwala A</AU>
<TI>Use of the modified Atkins diet for treatment of refractory childhood epilepsy: a randomized controlled trial</TI>
<SO>Epilepsia</SO>
<YR>2013</YR>
<VL>54</VL>
<NO>3</NO>
<PG>481-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-01-12 13:23:35 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Freeman-1999" MODIFIED="2011-06-03 12:41:29 +0100" MODIFIED_BY="[Empty name]" NAME="Freeman 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-06-03 12:41:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freeman JM, Vining EPG</AU>
<TI>Seizures decrease rapidly after fasting: preliminary studies of the ketogenic diet</TI>
<SO>Archives of Pediatric and Adolescent Medicine</SO>
<YR>1999</YR>
<VL>153</VL>
<NO>9</NO>
<PG>946-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freeman-2009" MODIFIED="2011-12-21 07:28:08 +0000" MODIFIED_BY="[Empty name]" NAME="Freeman 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-12-21 07:28:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freeman J, Vining E, Kossoff E, Pyzik P, Ye X, Goodman S</AU>
<TI>A blinded, crossover study of the efficacy of the ketogenic diet</TI>
<SO>Epilepsia</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>2</NO>
<PG>322-5</PG>
<IDENTIFIERS MODIFIED="2011-06-03 12:41:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hemingway-2001" MODIFIED="2016-01-12 13:23:35 +0000" MODIFIED_BY="[Empty name]" NAME="Hemingway 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-01-12 13:23:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hemingway C, Freeman JM, Pillas DJ, Pyzik PL</AU>
<TI>The ketogenic diet: a 3- to 6-year follow-up of 150 children enrolled prospectively</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>108</VL>
<NO>4</NO>
<PG>898-905</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kang-2011" MODIFIED="2015-12-12 12:15:43 +0000" MODIFIED_BY="[Empty name]" NAME="Kang 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-12-12 12:15:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Publication Type: JOURNAL ARTICLE&lt;/p&gt;" NOTES_MODIFIED="2015-12-12 12:15:43 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kang HC, Lee YJ, Lee JS, Lee EJ, Eom S, You SJ, et al</AU>
<TI>Comparison of short- versus long-term ketogenic diet for intractable infantile spasms</TI>
<SO>Epilepsia</SO>
<YR>2011</YR>
<VL>52</VL>
<NO>4</NO>
<PG>781-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2011" MODIFIED="2016-01-07 12:35:35 +0000" MODIFIED_BY="[Empty name]" NAME="Smith 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-01-07 12:35:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith M, Politzer N, Macgarvie D, McAndrews MP, del Campo M</AU>
<TI>Efficacy and tolerability of the Modified Atkins Diet in adults with pharmacoresistant epilepsy: a prospective observational study</TI>
<SO>Epilepsia</SO>
<YR>2011</YR>
<VL>52</VL>
<NO>4</NO>
<PG>775-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2016-01-07 12:35:51 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Hulshof-2014" MODIFIED="2016-01-07 12:35:45 +0000" MODIFIED_BY="[Empty name]" NAME="Hulshof 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-01-07 12:35:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hulshof HM, Carpay JA, Jansen FE, Braun KPJ</AU>
<TI>The modified Atkins diet in patients with refractory epilepsy and severe intellectual disability - design of a randomized controlled trial</TI>
<SO>Epilepsia</SO>
<YR>2014</YR>
<VL>55</VL>
<PG>205</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoon-2014" MODIFIED="2016-01-07 12:35:51 +0000" MODIFIED_BY="[Empty name]" NAME="Yoon 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-01-07 12:35:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoon JR, Lee E, Dong Kim H, Soo Lee J, Chul Kang H</AU>
<TI>Comparison of ketogenic diet and modified Atkins diet in children with epilepsy: a randomized controlled trial</TI>
<SO>Epilepsy Currents</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-01-20 14:51:42 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-01-12 13:24:42 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Atkins-1972" MODIFIED="2016-01-07 12:36:00 +0000" MODIFIED_BY="[Empty name]" NAME="Atkins 1972" TYPE="BOOK">
<AU>Atkins RC</AU>
<SO>Dr. Atkins' diet revolution; the high calorie way to stay thin forever</SO>
<YR>1972</YR>
<PB>D. McKay Co</PB>
<CY>Philadelphia, PA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2003" MODIFIED="2015-04-02 23:07:09 +0100" MODIFIED_BY="Graham Chan" NAME="Chang 2003" TYPE="JOURNAL_ARTICLE">
<AU>Chang BS, Lowenstein DH</AU>
<TI>Epilepsy</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>13</NO>
<PG>1257-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coppola-2002" MODIFIED="2016-01-07 12:36:06 +0000" MODIFIED_BY="[Empty name]" NAME="Coppola 2002" TYPE="JOURNAL_ARTICLE">
<AU>Coppola G, Veggiotti P, Cusmai R, Bertoli S, Cardinali S, Dionisi-Vici C, et al</AU>
<TI>The ketogenic diet in children, adolescents and young adults with refractory epilepsy: an Italian multicentric experience</TI>
<SO>Epilepsy Research</SO>
<YR>2002</YR>
<VL>48</VL>
<NO>3</NO>
<PG>221-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DiMario-2002" MODIFIED="2016-01-07 12:36:11 +0000" MODIFIED_BY="[Empty name]" NAME="DiMario 2002" TYPE="JOURNAL_ARTICLE">
<AU>DiMario FJ, Holland J</AU>
<TI>The Ketogenic diet: a review of the experience at Connecticut Children's Medical Center</TI>
<SO>Pediatric Neurology</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>4</NO>
<PG>288-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Geyelin-1921" NAME="Geyelin 1921" TYPE="JOURNAL_ARTICLE">
<AU>Geyelin HR</AU>
<TI>Fasting as a method for treating epilepsy</TI>
<SO>Medical Record</SO>
<YR>1921</YR>
<VL>99</VL>
<PG>1037-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Granata-2009" MODIFIED="2016-01-07 12:36:22 +0000" MODIFIED_BY="[Empty name]" NAME="Granata 2009" TYPE="JOURNAL_ARTICLE">
<AU>Granata T, Marchi N, Carlton E, Ghosh C, Gonzalez-Martinez J, Alexopoulos AV, et al</AU>
<TI>Management of the patient with medically refractory epilepsy</TI>
<SO>Expert Review of Neurotherapeutics</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>12</NO>
<PG>1791-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guelpa-1911" MODIFIED="2015-08-26 15:01:32 +0100" MODIFIED_BY="[Empty name]" NAME="Guelpa 1911" TYPE="JOURNAL_ARTICLE">
<AU>Guelpa G, Marie A</AU>
<TO>La lutte contre l'epilepsie par la desintoxication et par la re-education alimentaire</TO>
<SO>Revue de Therapie Medico-Chirurgide</SO>
<YR>1911</YR>
<VL>78</VL>
<PG>8-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2015-04-02 23:50:53 +0100" MODIFIED_BY="Graham Chan" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al; the GRADE Working Group</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS MODIFIED="2015-04-02 23:49:58 +0100" MODIFIED_BY="Graham Chan">
<IDENTIFIER MODIFIED="2015-04-02 23:49:58 +0100" MODIFIED_BY="Graham Chan" TYPE="DOI" VALUE="10.1136/bmj.39489.470347.AD"/>
<IDENTIFIER MODIFIED="2015-04-02 23:49:37 +0100" MODIFIED_BY="Graham Chan" TYPE="PUBMED" VALUE="18436948"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hauser-1990" MODIFIED="2016-01-07 12:36:34 +0000" MODIFIED_BY="[Empty name]" NAME="Hauser 1990" TYPE="BOOK">
<AU>Hauser WA, Hesdorffer DC</AU>
<SO>Epilepsy: Frequency, Causes, and Consequences</SO>
<YR>1990</YR>
<PB>Demos Publications</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-01-07 12:36:41 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hosain-2005" MODIFIED="2016-01-12 13:24:40 +0000" MODIFIED_BY="[Empty name]" NAME="Hosain 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hosain SA, La Vega-Talbott M, Solomon GE</AU>
<TI>Ketogenic diet in pediatric epilepsy patients with gastrostomy feeding</TI>
<SO>Pediatric Neurology</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>2</NO>
<PG>81-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kang-2005" MODIFIED="2016-01-12 13:24:42 +0000" MODIFIED_BY="[Empty name]" NAME="Kang 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kang HC, Kim YJ, Kim DW, Kim HD</AU>
<TI>Efficacy and safety of the ketogenic diet for intractable childhood epilepsy: Korean multicentric experience</TI>
<SO>Epilepsia</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>2</NO>
<PG>272-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirkham-2010" MODIFIED="2016-01-07 12:37:03 +0000" MODIFIED_BY="[Empty name]" NAME="Kirkham 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al</AU>
<TI>The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c365</PG>
<IDENTIFIERS MODIFIED="2015-04-03 00:01:53 +0100" MODIFIED_BY="Graham Chan">
<IDENTIFIER MODIFIED="2015-04-03 00:01:51 +0100" MODIFIED_BY="Graham Chan" TYPE="DOI" VALUE="10.1136/bmj.c365"/>
<IDENTIFIER MODIFIED="2015-04-03 00:01:34 +0100" MODIFIED_BY="Graham Chan" TYPE="PUBMED" VALUE="20156912"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kossoff-2005" MODIFIED="2015-03-20 10:37:40 +0000" MODIFIED_BY="[Empty name]" NAME="Kossoff 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kossoff EH, Thiele EA, Pfeifer HH, McGrogan JR, Freeman JM</AU>
<TI>Tuberous sclerosis complex and the ketogenic diet</TI>
<SO>Epilepsia</SO>
<YR>2005</YR>
<VL>46</VL>
<PG>1684-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kossoff-2008" MODIFIED="2016-01-07 12:37:14 +0000" MODIFIED_BY="[Empty name]" NAME="Kossoff 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kossoff EH, Rowley H, Sinha SR, Vining EPG</AU>
<TI>A prospective study of the modified Atkins diet for intractable epilepsy in adults</TI>
<SO>Epilepsia</SO>
<YR>2008</YR>
<VL>49</VL>
<NO>2</NO>
<PG>316-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawn-2004" MODIFIED="2015-04-02 23:22:24 +0100" MODIFIED_BY="Graham Chan" NAME="Lawn 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lawn ND, Bamlet WR, Radhakrishnan K, O'Brien PC, So EL</AU>
<TI>Injuries due to seizures in persons with epilepsy: a population-based study</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>9</NO>
<PG>1565-70</PG>
<IDENTIFIERS MODIFIED="2015-04-02 23:22:24 +0100" MODIFIED_BY="Graham Chan">
<IDENTIFIER MODIFIED="2015-04-02 23:21:47 +0100" MODIFIED_BY="Graham Chan" TYPE="PUBMED" VALUE="15534237"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2016-01-07 12:37:08 +0000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Merritt-1938" MODIFIED="2016-01-07 12:37:19 +0000" MODIFIED_BY="[Empty name]" NAME="Merritt 1938" TYPE="JOURNAL_ARTICLE">
<AU>Merritt HH, Putnam TJ</AU>
<TI>Sodium diphenyl hydantoin in the treatment of convulsive disorders</TI>
<SO>JAMA</SO>
<YR>1938</YR>
<VL>111</VL>
<PG>1068-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moesk-2009" MODIFIED="2016-01-07 12:37:31 +0000" MODIFIED_BY="[Empty name]" NAME="Moesk 2009" TYPE="JOURNAL_ARTICLE">
<AU>Moesk A, Natour H, Neufeld MY, Shiff Y, Vaisman N</AU>
<TI>Ketogenic diet treatment in adults with refractory epilepsy: a prospective pilot study</TI>
<SO>Seizure</SO>
<YR>2009</YR>
<VL>18</VL>
<PG>30-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nilsson-1999" MODIFIED="2016-01-07 12:37:37 +0000" MODIFIED_BY="[Empty name]" NAME="Nilsson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson L, Farahmond BY, Persson PG, Thiblin I, Tomson T</AU>
<TI>Risk factors for sudden unexpected death in epilepsy: a case control study</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<PG>888-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Connor-2014" MODIFIED="2016-01-07 12:37:42 +0000" MODIFIED_BY="[Empty name]" NAME="O'Connor 2014" TYPE="JOURNAL_ARTICLE">
<AU>O'Connor SE, Richardson C, Trescher WH, Byler DL, Sather JD, Michael EH, et al</AU>
<TI>The ketogenic diet for the treatment of pediatric status epilepticus</TI>
<SO>Pediatric Neurology</SO>
<YR>2014</YR>
<VL>50</VL>
<PG>101-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmidt-2002" MODIFIED="2015-04-02 23:26:51 +0100" MODIFIED_BY="Graham Chan" NAME="Schmidt 2002" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt D</AU>
<TI>The clinical impact of new antiepileptic drugs after a decade of use in epilepsy</TI>
<SO>Epilepsy Research</SO>
<YR>2002</YR>
<VL>50</VL>
<NO>1-2</NO>
<PG>21-32</PG>
<IDENTIFIERS MODIFIED="2015-04-02 23:26:51 +0100" MODIFIED_BY="Graham Chan">
<IDENTIFIER MODIFIED="2015-04-02 23:26:51 +0100" MODIFIED_BY="Graham Chan" TYPE="PUBMED" VALUE="12151114"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schwartz-1989" NAME="Schwartz 1989" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz RH, Eaton J, Bower BD, Aynsley-Green A</AU>
<TI>Ketogenic diets in the treatment of epilepsy: short-term clinical effects</TI>
<SO>Developmental Medicine and Child Neurology</SO>
<YR>1989</YR>
<VL>31</VL>
<PG>145-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwartzkroin-1999" MODIFIED="2010-01-29 11:43:30 +0000" MODIFIED_BY="[Empty name]" NAME="Schwartzkroin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Schwartzkroin PA</AU>
<TI>Mechanisms underlying the anti-epileptic efficacy of the ketogenic diet</TI>
<SO>Epilepsy Research</SO>
<YR>1999</YR>
<VL>37</VL>
<PG>171-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villeneuve-2004" MODIFIED="2015-04-02 23:34:46 +0100" MODIFIED_BY="Graham Chan" NAME="Villeneuve 2004" TYPE="JOURNAL_ARTICLE">
<AU>Villeneuve N</AU>
<TI>Quality-of-life scales for patients with drug-resistant partial epilepsy</TI>
<TO>Quelles echelles de qualite de vie pour les patients ayant une epilepsie partielle pharmaco-resistante</TO>
<SO>Revue Neurologique</SO>
<YR>2004</YR>
<VL>160</VL>
<NO>Spec No 1</NO>
<PG>5S376-93</PG>
<IDENTIFIERS MODIFIED="2015-04-02 23:34:46 +0100" MODIFIED_BY="Graham Chan">
<IDENTIFIER MODIFIED="2015-04-02 23:34:46 +0100" MODIFIED_BY="Graham Chan" TYPE="PUBMED" VALUE="15331986"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilder-1921" NAME="Wilder 1921" TYPE="JOURNAL_ARTICLE">
<AU>Wilder RM</AU>
<TI>The effects of ketonemia on course of epilepsy</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1921</YR>
<VL>2</VL>
<PG>307-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-01-20 14:45:50 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Levy-2003" MODIFIED="2016-01-20 14:44:26 +0000" MODIFIED_BY="[Empty name]" NAME="Levy 2003" TYPE="COCHRANE_REVIEW">
<AU>Levy RG, Cooper PP</AU>
<TI>Ketogenic diet for epilepsy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2016-01-20 14:44:26 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-01-20 14:44:26 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001903"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levy-2012" MODIFIED="2016-01-20 14:45:50 +0000" MODIFIED_BY="[Empty name]" NAME="Levy 2012" TYPE="COCHRANE_REVIEW">
<AU>Levy RG, Cooper PN, Giri P, Weston J</AU>
<TI>Ketogenic diet and other dietary treatments for epilepsy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2016-01-20 14:45:50 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2016-01-20 14:45:50 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001903.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2016-01-20 14:51:42 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-de-Kinderen-2011" MODIFIED="2016-01-20 14:50:49 +0000" MODIFIED_BY="[Empty name]" NAME="de Kinderen 2011" TYPE="JOURNAL_ARTICLE">
<AU>de Kinderen RJ, Lambrechts DA, Postulart D, Kessels AG, Hendriksen JG, Aldenkamp AP, et al</AU>
<TI>Research into the (cost-) effectiveness of the ketogenic diet among children and adolescents with intractable epilepsy: design of a randomized controlled trial</TI>
<SO>BMC Neurology</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>1</NO>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freeman-2009" MODIFIED="2016-01-20 14:51:03 +0000" MODIFIED_BY="[Empty name]" NAME="Freeman 2009" TYPE="JOURNAL_ARTICLE">
<AU>Freeman JM</AU>
<TI>The ketogenic diet: additional information from a crossover study</TI>
<SO>Journal of Child Neurology</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>4</NO>
<PG>509-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neal-2009a" MODIFIED="2016-01-20 14:51:27 +0000" MODIFIED_BY="[Empty name]" NAME="Neal 2009a" TYPE="OTHER">
<AU>Neal E, Chaffe H, Fitzsimmons G, Edwards N, Lawson M, Schwartz R, et al</AU>
<TI>A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy - efficacy and tolerability after 12 months [abstract no: T148]</TI>
<SO>Epilepsia</SO>
<YR>2009</YR>
<VL>50 Suppl 4</VL>
<PG>86-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Porta-2009" MODIFIED="2016-01-20 14:51:42 +0000" MODIFIED_BY="[Empty name]" NAME="Porta 2009" TYPE="JOURNAL_ARTICLE">
<AU>Porta N, Vallee L, Boutry E, Fontaine M, Dessein AF, Joriot S, et al</AU>
<TI>Comparison of seizure reduction and serum fatty acid levels after receiving the ketogenic and modified Atkins diet</TI>
<SO>Seizure</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>5</NO>
<PG>359-64</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-01-12 13:22:53 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-01-12 11:20:10 +0000" MODIFIED_BY="[Empty name]" SORT_BY="USER" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-01-07 11:46:35 +0000" MODIFIED_BY="[Empty name]" ORDER="1" STUDY_ID="STD-Bergqvist-2005">
<CHAR_METHODS MODIFIED="2016-01-07 11:46:35 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, single-centre study comparing Fast KD and Grad KD over a 3-month period. Baseline data of seizure activity was collected 28 days prior to diet initiation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-07 11:46:35 +0000" MODIFIED_BY="[Empty name]">
<P>48 children, 24 in each of the 2 arms, aged 1-14 years (mean 5.3, SD 2.7 years), having &#8805; 1 seizures per 28 days, tried at least 3 AEDs and a discontinuation of steroidal medication 3 months previous. Study done in Philadelphia, USA. All generalised and partial seizures included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-07 11:46:35 +0000" MODIFIED_BY="[Empty name]">
<P>Speed of introduction of KD: Fast KD or Grad KD</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-01-07 11:46:35 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Proportion of participants with &gt; 50% seizure reduction in target seizure type</LI>
<LI>Level of ketosis</LI>
<LI>Adverse effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-07 11:46:35 +0000" MODIFIED_BY="[Empty name]">
<P>In the first 6 days of the KD trial, 2 participants dropped out, 1 with pancreatitis (Fast KD) and 1 due to viral gastrointestinal illness (Grad KD). 3 further drop-outs occurred in the Fast KD prior to 3 months' follow-up, 1 due to respiratory distress and 2 due to lack of efficacy. In the Grad KD group, 1 participant withdrew due to lack of efficacy</P>
<P>Exclusion criteria: children with metabolic disorders, genetic disorders and known or suspected neurodegenerative disorders. 42% of children included in the study had cerebral palsy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-07 11:46:46 +0000" MODIFIED_BY="[Empty name]" ORDER="2" STUDY_ID="STD-Kossoff-2007">
<CHAR_METHODS MODIFIED="2016-01-07 11:46:45 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, cross-over controlled trial to compare daily carbohydrate limits of 10 g and 20 g, using the MAD over a 6-month period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-07 11:46:45 +0000" MODIFIED_BY="[Empty name]">
<P>20 children, aged 3-18 years with intractable epilepsy, with a prior use of at least 2 AEDs and experiencing daily seizures. All seizure types included. Study conducted in Baltimore USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-07 11:46:45 +0000" MODIFIED_BY="[Empty name]">
<P>MAD with randomisation either to 10 g (10 children) or 20 g (10 children) of carbohydrate and cross-over at 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-01-07 11:46:45 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Seizure reduction</LI>
<LI>Level of ketosis</LI>
<LI>Tolerability</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-07 11:46:46 +0000" MODIFIED_BY="[Empty name]">
<P>3 (30%) participants dropped out in the 10 g carbohydrate/day group and 5 (50%) participants in the 20 g carbohydrate/day group by 6 months, no significance was found between the groups (P value = 0.33). Reasons for drop-out were not stated</P>
<P>Exclusion criteria: children with prior experience of the diet for &gt; 7 days, hypercholesterolaemia, kidney dysfunction, body mass index &lt; 3% for age and children with heart disease</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-07 11:46:52 +0000" MODIFIED_BY="[Empty name]" ORDER="3" STUDY_ID="STD-Neal-2008">
<CHAR_METHODS MODIFIED="2016-01-07 11:46:52 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, non-blinded, controlled trial comparing KD (classic and MCT combined) to controls over a 3-month period, with a follow-on study then compared classic KD versus MCT KD over a 12-month period. 4-week seizure baseline completed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-07 11:46:52 +0000" MODIFIED_BY="[Empty name]">
<P>145 children (aged 2-16 years), with daily seizures and &gt; 7 seizures/week, who had not responded to &#8805; 2 AEDs who had not previously been treated with a KD. Study conducted in the UK. All seizure types included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-07 11:46:52 +0000" MODIFIED_BY="[Empty name]">
<P>Participants were randomised to commence a KD (either classic or MCT) immediately (73 participants) or after a further 3 months of seizure recording (control group, 72 participants)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-01-07 11:46:52 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Reduction in seizure frequency</LI>
<LI>Tolerability</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-07 11:46:52 +0000" MODIFIED_BY="[Empty name]">
<P>Of the 65 who commenced the diet, 10 dropped out. Of these, 6 had poor dietary tolerance, 3 withdrew due to parental unhappiness, 1 increased seizures and 1 excluded due to inadequate data. In the control group, 15 participants were excluded due to inadequate data</P>
<P>Exclusion criteria: hyperlipidaemia, renal stones or organic acid deficiency syndromes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-07 11:46:58 +0000" MODIFIED_BY="[Empty name]" ORDER="4" STUDY_ID="STD-Seo-2007">
<CHAR_METHODS MODIFIED="2016-01-07 11:46:58 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre randomised controlled trial, to compare 3 : 1 and 4 : 1 KD. Baseline period lasted 2 months. After a 3-month period of the diet, participants who were seizure free in the 4 : 1 group were recommended to change to a 3 : 1 ratio, and participants who were not seizure free in the 3 : 1 group were recommended to change to a 4 : 1 ratio and were re-evaluated after a further 3 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-07 11:46:58 +0000" MODIFIED_BY="[Empty name]">
<P>76 children (aged 4 months to 16 years), with &gt; 4 seizures/months and seizures were not controlled by at least 3 AEDs. Study done in Korea. All seizure types included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-07 11:46:58 +0000" MODIFIED_BY="[Empty name]">
<P>Participants were randomised into 2 groups, 4 : 1 KD group (40 participants) and 3 : 1 KD group (36 participants) and the diet was followed for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-01-07 11:46:58 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Seizure reduction rate</LI>
</UL>
<UL>
<LI>Tolerability</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-07 11:46:58 +0000" MODIFIED_BY="[Empty name]">
<P>6 participants dropped out in both of the original groups. 2 of participants in the 3 : 1 group dropped out due to diet intolerance and 1 participant in the 4 : 1 KD group. 1 participant in the 3 : 1 group dropped out due to acute pancreatitis. Other reasons for drop-out of participants were not stated.</P>
<P>Exclusion criteria: children with metabolic disorders, known or suspected neurological degenerative disorders, or both</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-12 11:20:07 +0000" MODIFIED_BY="[Empty name]" ORDER="5" STUDY_ID="STD-El_x002d_Rashidy-2013">
<CHAR_METHODS MODIFIED="2016-01-07 11:47:05 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre randomised controlled trial to compare the 2 different dietary interventions (MAD and classic KD in form of 4 : 1 liquid diet) and a control group (AED)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-07 11:47:05 +0000" MODIFIED_BY="[Empty name]">
<P>40 children aged 12-36 months (mean 27.13, SD 6.63) with symptomatic intractable epilepsy. Study done in Egypt</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-07 11:47:05 +0000" MODIFIED_BY="[Empty name]">
<P>Participants were randomised into 1 of 3 groups; MAD (15 participants), KD (10 participants) and control (15 participants). Data were collected at 3 and 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-01-07 11:47:05 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Seizure reduction rate</LI>
</UL>
<UL>
<LI>Adverse effects</LI>
</UL>
<UL>
<LI>Attrition rate</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-07 11:47:05 +0000" MODIFIED_BY="[Empty name]">
<P>2 participants in the MAD group dropped out of the trial as they could not accept the diet and experienced weight loss. From the results, it could be inferred that these participants dropped out between the 3- and 6-month reviews. 2 participants from the classic KD group dropped out due to intolerance; however, it was unclear when these participants dropped out</P>
<P>Exclusion criteria: children &lt; 1 year, diagnosed with idiopathic epilepsy or with other systemic chronic conditions</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-07 11:47:20 +0000" MODIFIED_BY="[Empty name]" ORDER="6" STUDY_ID="STD-Raju-2011">
<CHAR_METHODS MODIFIED="2016-01-07 11:47:20 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, non-blinded, open-label, parallel controlled trial, to compare a 4 : 1 and a 2.5 : 1 ratio KD over a 3-month period</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-07 11:47:20 +0000" MODIFIED_BY="[Empty name]">
<P>38 children aged 6 months to 5 years, with refractory epilepsy, at least 2 seizures/month, despite appropriate use of at least 2 AED and at least 1 newer AED. Study done in India</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-07 11:47:20 +0000" MODIFIED_BY="[Empty name]">
<P>Participants were randomised into 1 of 2 groups; a 4 : 1 ratio KD (19 participants) and 2.5 : 1 KD (19 participants) and followed for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-01-07 11:47:20 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>&gt; 50% reduction in seizure frequency</LI>
</UL>
<UL>
<LI>Adverse effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-07 11:47:20 +0000" MODIFIED_BY="[Empty name]">
<P>3 participants in each group dropped out of the study. Reasons for drop-out in 4 : 1 KD group were refusal to eat, unsatisfactory seizure control and non-acceptance by other family members. In 2.5 : 1 KD group, 2 participants dropped out due to unsatisfactory seizure control and 1 due to refusal to eat</P>
<P>Exclusion criteria: known or suspected inborn errors of metabolism, systemic illness or surgical remediable causes of epilepsy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-12 11:20:10 +0000" MODIFIED_BY="[Empty name]" ORDER="7" STUDY_ID="STD-Sharma-2013">
<CHAR_METHODS MODIFIED="2016-01-07 11:47:26 +0000" MODIFIED_BY="[Empty name]">
<P>Open-label, single-centre, parallel-group, randomised, controlled trial, to compare the MAD to a control group over a 3-month period. Authors noted the study design to be similar to that of <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK>. There was a 4-week baseline of seizure frequency</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-07 11:47:26 +0000" MODIFIED_BY="[Empty name]">
<P>102 children aged 2-14 years with refractory epilepsy and 2-14 daily seizures, having previously tried 3 AEDs. Study conducted in India</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-07 11:47:26 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised into 1 of 2 groups; MAD (50 participants) or a normal diet (52 participants) for a period of 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-01-07 11:47:26 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Seizure frequency</LI>
</UL>
<UL>
<LI>Tolerability</LI>
</UL>
<UL>
<LI>Adverse effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-07 11:47:26 +0000" MODIFIED_BY="[Empty name]">
<P>4 children reported to have dropped out of the trial. 2 secondary to lower respiratory tract infections, 1 secondary to hyperammonaemic encephalopathy and 1 as the child and family found the diet too restrictive. In the control group, 3 participants were lost to follow-up</P>
<P>Exclusion criteria: known or suspected inborn errors of metabolism, systemic illness or motivational issues the family that would prelude compliance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AED: antiepileptic drug; Fast FD: fasting-onset ketogenic diet; Grad KD: gradual-onset ketogenic diet; KD: ketogenic diet; MAD: modified Atkins diet; MCT: medium-chain triglyceride; SD: standard deviation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-01-12 13:22:53 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-01-12 11:20:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freeman-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-07 11:47:49 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome measures did not match inclusion criterion as duration of study was 12 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-07 11:47:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Freeman-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-07 11:47:44 +0000" MODIFIED_BY="[Empty name]">
<P>Study was very brief and lasted only 12 days - duration of the study did not fit entry criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-07 11:47:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hemingway-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-07 11:47:40 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-12 13:22:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kang-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-12 13:22:44 +0000" MODIFIED_BY="[Empty name]">
<P>Refractory infantile spasm population, outcome measures did not match inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-07 11:47:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-07 11:47:37 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-01-07 11:48:06 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-01-07 11:47:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hulshof-2014">
<CHAR_STUDY_NAME MODIFIED="2016-01-07 11:47:54 +0000" MODIFIED_BY="[Empty name]">
<P>The |Modified Atkins Diet for Epilepsy: an RCT</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-01-07 11:47:54 +0000" MODIFIED_BY="[Empty name]">
<P>A single-centre, parallel, unblinded randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-07 11:47:54 +0000" MODIFIED_BY="[Empty name]">
<P>Aimed to recruit 54 people, aged &gt; 18 years, adults with refractory epilepsy that was controlled by 2 AEDs. Included participants must have had &#8805; 2 seizures/month and have moderate-to-severe intellectual disability. Potential participants were excluded if they had undergone epilepsy surgery in the last 6 months or were awaiting surgery; underwent implantation of vagal nerve stimulation in the last 6 months; have used the MAD or KD for &gt; 7 days in the last year</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-07 11:47:54 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention group treated with the MAD for at least 4 months, with a total follow-up of at least 6 months</P>
<P>Control group comprised a waiting list in which participants can begin the MAD diet after the 4-month trial period, the control group can be started on the MAD as well, in which efficacy, tolerability and safety will also be evaluated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-01-07 11:47:54 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<UL>
<LI>Number of responders 4 months after randomisation, compared between the intervention and the control group. Responder is defined by &gt; 50% reduction in seizure frequency</LI>
</UL>
<P>Secondary outcomes:</P>
<UL>
<LI>Retention of the diet; change in daily functioning; feasibility of the MAD in this population and setting; adverse events attributable to the MAD; predictive factors of efficacy of the diet</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2016-01-07 11:47:54 +0000" MODIFIED_BY="[Empty name]">
<P>8 January 2014</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-08-15 10:27:53 +0100" MODIFIED_BY="[Empty name]">
<P>H.M.Hulshof-3@umcutrecht.nl</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-01-07 11:47:54 +0000" MODIFIED_BY="[Empty name]">
<P>On the 28 July 2015, the study authors reported that this trial was ongoing and was now recruiting from an additional site. They expect to end recruitment at the end of July 2016</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-01-07 11:48:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yoon-2014">
<CHAR_STUDY_NAME MODIFIED="2016-01-07 11:48:00 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of Ketogenic Diet and Modified Atkins Diet in Children with Epilepsy: a Randomized Controlled Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-01-07 11:48:00 +0000" MODIFIED_BY="[Empty name]">
<P>Open-label, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-01-07 11:48:01 +0000" MODIFIED_BY="[Empty name]">
<P>108 children aged 2-16 years who had at least 1 seizure/week or &gt; 4 seizures/month, had failed to respond to at least 2 AEDs and had not been treated previously with the diet therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-07 11:48:01 +0000" MODIFIED_BY="[Empty name]">
<P>KD vs. MAD assessed at 1, 3 and 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-01-07 11:48:01 +0000" MODIFIED_BY="[Empty name]">
<P>Primary endpoint was a reduction in seizures at 6 months on diet</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-08-15 10:36:10 +0100" MODIFIED_BY="[Empty name]">
<P>HIPO0207@yuhs.ac</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-01-07 11:48:01 +0000" MODIFIED_BY="[Empty name]">
<P>On 24 July 2015, study authors reported that the full-text paper reporting the results of this study was under review with <I>Epilepsia</I>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>AED: antiepileptic drug; KD: ketogenic diet; MAD: modified Atkins diet.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-01-07 11:47:29 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-01-07 11:47:28 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-24 14:26:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-2005">
<DESCRIPTION>
<P>Stratified by age (1-2 years and 2-14 years); randomisation in permuted blocks of random size (2-4)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:47:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Rashidy-2013">
<DESCRIPTION>
<P>Although the paper stated that participants were 'randomly assigned', there was no information regarding how the randomisation sequence was generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-01 12:29:24 +0000" MODIFIED_BY="Pratima Giri" RESULT="UNKNOWN" STUDY_ID="STD-Kossoff-2007">
<DESCRIPTION>
<P>Method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:46:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neal-2008">
<DESCRIPTION>
<P>Minimisation method with stratification</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-15 10:58:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Raju-2011">
<DESCRIPTION>
<P>Sequence generation was computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:47:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seo-2007">
<DESCRIPTION>
<P>Although study stated that participants were randomly assigned to each group, there was no information regarding how randomisation was achieved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:47:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2013">
<DESCRIPTION>
<P>Randomisation sequence was computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-01-07 11:47:16 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:46:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-2005">
<DESCRIPTION>
<P>Randomisation through permuted blocks of random size of groups of 2 or 4 participants in order to prevent any ability to guess the next assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:47:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Rashidy-2013">
<DESCRIPTION>
<P>There was no information suggesting whether allocation was concealed or not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-01 12:29:20 +0000" MODIFIED_BY="Pratima Giri" RESULT="UNKNOWN" STUDY_ID="STD-Kossoff-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-28 13:08:49 +0000" MODIFIED_BY="Pratima Giri" RESULT="YES" STUDY_ID="STD-Neal-2008">
<DESCRIPTION>
<P>Computer program</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-15 10:59:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Raju-2011">
<DESCRIPTION>
<P>Opaque sealed envelopes were used to conceal allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 10:35:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seo-2007">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-15 11:02:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2013">
<DESCRIPTION>
<P>Opaque sealed envelopes were used to conceal allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-01-07 11:47:16 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-01 15:10:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bergqvist-2005">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-01-07 11:47:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El_x002d_Rashidy-2013">
<DESCRIPTION>
<P>Blinding was not discussed in this paper but considering the design of the study, binding of participants and study personnel does not seem possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-01 12:29:18 +0000" MODIFIED_BY="Pratima Giri" RESULT="NO" STUDY_ID="STD-Kossoff-2007">
<DESCRIPTION>
<P>Non-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-12-01 14:41:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neal-2008">
<DESCRIPTION>
<P>Non-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-08-15 10:59:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raju-2011">
<DESCRIPTION>
<P>Study was unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-01-07 11:47:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Seo-2007">
<DESCRIPTION>
<P>Study did not report whether blinding was undertaken although it seems from the design of the study that blinding would not be possible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-08-15 11:02:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-2013">
<DESCRIPTION>
<P>Unblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-01-07 11:47:28 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.03" NO="3">
<NAME/>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2016-01-07 11:46:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-2005">
<DESCRIPTION>
<P>Similar attrition rate in both groups, numbers too small for statistical analysis</P>
<P>1 participant dropped out in each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2016-01-07 11:47:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El_x002d_Rashidy-2013">
<DESCRIPTION>
<P>Study attrition was reported but intention-to-treat analysis was not carried out. Reasons for drop-outs were likely to be related to interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2016-01-07 11:46:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kossoff-2007">
<DESCRIPTION>
<P>Greater attrition rate in 20 g carbohydrate group but not significant. 3/10 in 10 g carbohydrate and 5/10 in 20 g carbohydrate group did not complete the study. P value of 0.33</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2015-08-05 11:42:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neal-2008">
<DESCRIPTION>
<P>High level of missing data in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2016-01-07 11:47:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Raju-2011">
<DESCRIPTION>
<P>Attrition was reported and was fairly equal across the groups. Intention-to-treat analysis carried out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2016-01-07 11:47:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seo-2007">
<DESCRIPTION>
<P>Number of drop-outs and reasons for drop-outs were reported and an intention-to-treat analysis was completed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2016-01-07 11:47:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2013">
<DESCRIPTION>
<P>Study attrition reported and intention-to-treat analysis carried out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-01-07 11:47:29 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-26 11:54:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bergqvist-2005">
<DESCRIPTION>
<P>Protocol unavailable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:47:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Rashidy-2013">
<DESCRIPTION>
<P>Emailed author regarding protocol, awaiting response from co-authors. Protocol currently unavailable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:46:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kossoff-2007">
<DESCRIPTION>
<P>Protocol received. No evidence to suggest selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:46:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neal-2008">
<DESCRIPTION>
<P>Initial application protocol received</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-26 11:43:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Raju-2011">
<DESCRIPTION>
<P>Protocol unavailable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 10:36:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seo-2007">
<DESCRIPTION>
<P>Protocol unavailable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:47:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sharma-2013">
<DESCRIPTION>
<P>Protocol available 15 August 2015 (clinicaltrials.gov/ct2/show/NCT00836836)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-01-07 11:47:29 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:46:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-2005">
<DESCRIPTION>
<P>All participants admitted received same care</P>
<P>No other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:47:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El_x002d_Rashidy-2013">
<DESCRIPTION>
<P>No measure of seizure frequency reported at baseline. 20% of participants in the classic KD group had infantile spasms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-01 12:29:30 +0000" MODIFIED_BY="Pratima Giri" RESULT="YES" STUDY_ID="STD-Kossoff-2007">
<DESCRIPTION>
<P>Same care to both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-01 12:30:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neal-2008">
<DESCRIPTION>
<P>Same care to both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:47:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Raju-2011">
<DESCRIPTION>
<P>Participants were all &lt; 18 years of age and there was a high rate of co-morbidity</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-05 10:36:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seo-2007">
<DESCRIPTION>
<P>No other sources of bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-07 11:47:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-2013">
<DESCRIPTION>
<P>Excluded participants where motivational issues within the family</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-01-07 11:49:25 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-01-07 11:49:25 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-01-07 11:48:11 +0000" MODIFIED_BY="[Empty name]">Ketogenic diet or other dietary treatments for people with epilepsy</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Ketogenic diet or other dietary treatments for peoplewith epilepsy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with epilepsy<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> ketogenic diet or other dietary treatments<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Ketogenic diet or other dietary treatments</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Seizure freedom</B>
</P>
<P>
<B>100%</B>
</P>
<P>Number of people</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>256</P>
<P>(4)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P>All trials included in this table assessed seizure freedom after 3 months. For more information on seizure freedom after longer periods of dietary interventions, see <LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>
</P>
<P/>
<P>3 studies reported similar rates of seizure freedom. <LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK> compared fasting-onset KD (3/24) and gradual-onset KD (5/24); <LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK> compared 4 : 1 KD (5/19) and 2.5 : 1 KD (4/19) and <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK> compared MCT (1/49) and KD (1/45)</P>
<P/>
<P>
<LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK> reported 22/40 participants became seizure free in the 4 : 1 KD group compared with 11/36 in the 3 : 1 KD group. However, it was unclear whether this difference was statistically significant</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Seizure reduction </B>
</P>
<P>
<B>&gt; 50%</B>
<BR/>Number of people</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>387<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2 studies found no significant difference between comparisons made; <LINK REF="STD-Bergqvist-2005" TYPE="STUDY">Bergqvist 2005</LINK> reported no significant difference in seizure reduction (&gt; 50% reduction) between the fasting-onset or gradual-onset KD and <LINK REF="STD-Raju-2011" TYPE="STUDY">Raju 2011</LINK> reported no significant difference in seizure reduction between a 4 : 1 KD and a 2.5 : 1 KD</P>
<P>4 studies noted significant differences in seizure reduction between diets examined; <LINK REF="STD-Kossoff-2007" TYPE="STUDY">Kossoff 2007</LINK> reported fewer seizures in 10 g carbohydrate group than the 20 g carbohydrate group of MAD, <LINK REF="STD-Neal-2008" TYPE="STUDY">Neal 2008</LINK> reported diet group had significantly higher seizure reduction than controls, <LINK REF="STD-Seo-2007" TYPE="STUDY">Seo 2007</LINK> reported fewer seizures for 4 : 1 group than 3 : 1 group and <LINK REF="STD-Sharma-2013" TYPE="STUDY">Sharma 2013</LINK> reported significantly more participants in the MAD group compared with participants in the control group</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects </B>
<BR/>Number of people</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>427<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>We list a summary of all adverse effects experienced within dietary intervention groups. For further detail of adverse effects reported in each study, see <LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>
</P>
<P>The most frequent adverse effects reported by participants in dietary intervention groups were: vomiting and constipation. Other adverse effects reported included diarrhoea, dysphagia, lethargy, lower respiratory tract infection, hyperammonaemic encephalopathy, weight loss, nausea, infections (pneumonia, sepsis), acute pancreatitis, decrease in bone matrix density, gallstones, fatty liver, nephrocalcinosis, hypercholesterolaemia, status epilepticus, acidosis, dehydration, tachycardia, hypoglycaemia, hunger and abdominal pain</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Attrition rate</B>
</P>
<P>Number of people</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>427</P>
<P>(7)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P>We summarise the attrition rates for each dietary intervention. For reasons for drop-outs, see <LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK>
</P>
<P>Overall the attrition rate in all dietary interventions ranged from 4.2% to 20.8%</P>
<P>Attrition rates in 4 : 1 KD groups ranged from 4.2% to 20.8%, in 3 : 1 KD was 16.7%, in 2.5 : 1 KD was 15.8%</P>
<P>Attrition rates for MAD groups ranged from 8% to 50%</P>
<P>Attrition rates for control groups ranged from 5.8% to 23.4%</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; KD: ketogenic diet; MAD: modified Atkins diet; MCT: medium-chain triglyceride.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Studies are heterogeneous with regards to interventions examined and comparisons made.<BR/>
<SUP>2</SUP> Relatively low overall sample size. Confidence in results from small number of participants is low.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-08-26 08:22:32 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2016-01-07 12:37:53 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-01-07 12:37:53 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAANMCAYAAAB2KSuMAABPEUlEQVR42u2df2RWb/z/3yRJkshk
kkQmkyQmyVsSk+T9RyLzNnl7i0mSTCSZTGKSTBKTZJKReZtkRiaZychMJolJkkwkSZLr+31en8+5
P9d9ds51nXP/2O4fjwe3dt/3+XXd53W9Huec63RefxiHP/74g1cTvWoN9gnxB/XJH24nhibb+TW0
z4k/4g/qXCTsUDozCQXY91DGfmRHEgR/NOW6gfgDRAKIBIg/QCSASIg/4o8YQCRARyaJADGASICO
TBIBYgAQCSASIP4AkQAiqQfm5uYIGkQCWUTy/ft309PTY9atW2fWrFljTpw4Yb58+VI0zcWLF836
9evN2rVr7fefPn0qfKdpjx07Zr/TMk6ePGk+f/5MkNPGzOv2xddytNv93v1b/WGlfr9GjEdE0sAi
OXfunLl9+7b5/fu3falTqzNHDAwMmMHBwcL3/f395uDBg4Xvr169avr6+grfP3jwwFy+fJkgp42Z
1h2Kr+UWCWdwtAlKEMnGjRttB4749etX0ZHY9u3b7VmLy+rVqwt/Hz582Lx+/bpo/iNHjniDaXp6
2rS0tJi9e/cWCWnDhg32rOb8+fNF8/z8+dN0d3fbI9a2tjYzNTW15IhW8+l7JaEPHz5416f2njlz
xh4Ft7a2mocPHxYF+ZMnT2wbV61aZXbt2mUmJyfpyFVadyi+4rx7965wBqzpFA+jo6OF70P7NvR9
9HfS86LibQjF3b1798zWrVttHGlbnz59mrkdiATqSiRxlLSVdJP4+vWrTfhdXV2Fz9QhXRFFn/mC
6ezZs3aejx8/2s/u3LljO50+k4jUua9fv16Y58qVK2ZkZMT+PTY2Znbu3Fn47saNG0VHtFqWpONb
382bN821a9fsZ7oMd+DAgaIgdzv9+Pi4TXZ05OqvOym+4uzevdsMDw8X9rf2vRuvoX0b+j7t7/j7
LHEnUURyUTy5ggy1A5FAXYtEl6aUuONo7ENHX3q9evXKe/ToO6LUdrhHbmLPnj1LZOQmb4kj/n1E
e3u7lZ8rwk2bNnnXpzMTd56ZmZmiIFeHjsRFR16edafFVxZ0xJ9134a+zyqSUuIu9Bu47UAkULci
WVxctB1aZwVp6HRel3uSgj+rSJKmj19KcJfrW15o/Wnrc5Gk3Ol0FqL3EpzGf+jIy7fueHwloUuV
OtjRmYsSevxs0rdvQ99nFUkpcRf/zNcORAJ1KRLJ4++//w7ecaXp3A6TdBkrdGkriwyyiinpu1CH
DM0TdXJdRuvs7DS9vb105GVadzy+4ty/f9+eoQ4NDZmJiQl7udInivi688SLTySlxJ37WagdiATq
TiQ6E9EtwAsLC0u+02UeVy7xU3glWnew9MePH967bpK2Q0eguj6exo4dO1IvbWne+CUG92aBpPXt
27evaB7dLJD2+8zOzjZMB6hFkYTiK+kgxY0Vxay77NC+DX2fVSSlxJ37WagdiATqSiQvXrwwf/75
Z+q9+7rU4N7ee+nSJfuK0OBoNHipl46wfJeDkrZDA5fuMvTelZFO/3W5STx79mzJYPutW7cK8+pW
ZonHtz4Ncuo202jA9dChQ0XTafm6c0vEB0npyJVddyi+4uguqOjuJkmgo6OjaNmhfRv63v1bd1Rp
nCMSRnywPW/cuZ+F2oFIoK5EsmXLFm95TF1q0F1POtrSQKg6votOydUZ9b1eR48eXfIfGrMEk/7v
iY7StAzd7RLdYRWd5ej/tiih61qyBkjjySgaqNWdM2/fvg2uT/9/QUe+uuVYd9y40+myltYT3bYZ
SYWOXPl1h+IrzvPnz+2NGNovEr5uiogv27dvQ9+7f+vOwSiuk9qQN+7cz0LtQCRQd5e2oGmCgCQC
xAAgEkAkQPwBIgFEAsQfIBKgI5NEgBhAJEBHJokAMQCIBBAJEH+ASACRAPEHiAToyCQRIAYQybJQ
K6VLm7WEKiJpLOotjomBBhZJqdXjSsFXujQqJqUn7lZivb75V7KE6kp2OkRS/e1txv6ESBDJsu58
37LiFeSquS7fw/gQCSKp5vY2Yn9CJIgkVxlS4SuJ6ysv6itdmqWsqW+9Wbbb3cakdekBfGllUdPK
A4dKrYY6ktqkbVa5Y1XIiz9rybdNjSKSRiu93Gz9CZEgkiU7N1SGNFQSN1Re1Hcm4PsutN7Qdmc5
I9HDJn3bHS/Xm6XUqm+9ao/qnETbvH///iW/h2+bGkkkjVR6uRn7EyJBJLnKkIZK4obKi5Ya+KH1
hrY7i0hC2x3/PkupVd96VRfDfXR/UsnXvKVa61UkjVR6uRn7EyJBJLnLlPpK4oaSZ6mBn7cUb3y7
s4gkz3aLckutxgdKfSVfG10kSb9jvZZebsb+hEgQSa7yoaGSuNUK/FJK8VZbJOWWWs1TO7zZRFLP
pZebsT8hEkSSqwxpqCRutQI/tN48pXMrJZK8pVbjpVRVEc8tMfvq1StEknF/13Lp5WbsT4gEkeQq
QxoqiRsKfF/pUl/gh9Yb2u44vu3IKpJQqVV3gPb9+/d20NQ32K72IJJs+7uWSy83Y39CJIgkd5lS
X0ncUOD7SpeGzhJ8682y3S6hEqpZRCJ8pVajhKPLCEpkSkTx5aizant1i6W2OXTk3CwiCe3vWi69
3Iz9CZEgEqgRlBy3bNmyIsl8JUUCTZWE+BEQCVQSHe1p8Da6l19H0b5BXEQCiAQQCRQxMTFh79fX
pQX9z/YLFy5YoSASQCSASICOTBIBYgCRAB2ZJALEACASQCRA/AEiAUQCxB8gEqAjk0SAGEAkfpq1
bC0duTLrbsb4odQzNIVI8kwbf4otwURHzrPuZix7XA9tRiSwrCLJGxwEEyLxfd4MIqmHNiMSyCWS
UFnNd+/e2Wfx6AFxes6QSpuOjo4WAiNe0tM3fTSPHjQXlUo9cuRI0bOSQvOHyp76SogSBLUlkkYu
e5y2PaW0ORTXab8J8QfLJpJQWc3du3fbp4FGTwpVJ1PApgVHlumj6oD6/vHjx+bUqVOZ5/eVPQ2V
ECUI6uOMpN7LHufdntDys5Tkjf8mxB8sq0hKKasZquIWmt49A1Hwq/Jc1vl9ZU9DJUQJgvoQSb2X
Pc67PaHll1KSl/iDZRVJlrKaOm1WDYiuri7bSUKPWM87fXwbfPP7yp6GSogSBPU5RlJvZY/zbk+W
app5S/ISf7CiIonv8Pv379vCPkNDQ/ZBgzp19nWyvNPHO3Jo/kg0SWVPkUZziqTWyh7n3Z7Q8ksp
yUv8wbKKJFRWUwOQblnOeMnY+HKzTD8/P1902u/W4QjN7xIvexoqIUoQNKZIaq3scd7tCS2/lJK8
xB8sq0hCZTV1J0l015Qko07nK/cZml5/Hz582CwuLtp1aqDfHWwPze8rexoqIUoQ1J5IGrHscWh7
8ra5lJK8xB8sq0iEr6zm8+fP7cCeOqOSuAa6feU+Q9Prb61D69I8koo7UBiaP1T2NFRCFJHU1rob
teyxb3vytjkU14gEakIkgEhIIv/HcpQ9Jv4AkQAduYGSyEqUPSb+AJEAHbmBkshKlD0m/gCRAB2Z
JALEACIBOjJJBIgBQCSASID4A0QCiASIP0AkQEcmiQAxgEiAjkwSAWIAGkAkoW0kEBEJEH+ASAg0
RALEHzSaSMopXZulrG68BKgeVBeV2dX0U1NTRdOHyqy6f+the6HypGnlU+nItbHuUPyVU0I3b/yF
4j20rYBImlYk5ZSuzVJWN14CVAWrogqHeiyFHszoTh8qs+r+LYmlTRsqn0pHro11++Kv3BK6eeMv
FO++bQVE0tQiqXTp2njltngJUHXc+DJ906c9+TU0bah8Kh25Ntbti79yS+jmjb9QvPu2FRBJU4uk
3NK15ZbVDQWaTyS+aUPlU+nItbFuX/yVW0I3b/yF4t23rYBImlokkQxKKV1bSlnd5RJJllr0dOTa
WHda/JVbQjdv/GUp1Zy2rYBIml4kEXlL1+YtwytUWMh3aatSIgmVT6Uj1966k+KvnBK6eeMvT6nm
+LYCImlqkZRTujZLWd04ugymSwTi2bNnSwbbKyWSUPlUOnJtrDsUf+WU0M0bf6F4920rIJKmFkk5
pWuzlNWNo+pzJ06csPNovRoEr4ZIhK98Kh25NtYdir9ySujmjb9QvIe2FRAJl7YaHMqn8h8SAZEA
IskF5VMRCRB/gEjKgvKpiASIP0AkgEiA+ANEAnRkkggQA4gE6MgkESAGAJEAIgFEAogEEAkQf4BI
AJEA8QeIBOjIJBEgBhAJ0JFJIkAMACIBRALEHyASQCRA/AEiAToySQSIAUQCdGSSCBADgEgAkQDx
B9Xfh+xIOjHbAOx7KFsk7FA6MdsC7HMoWyTRjuXVPK9aTCy8iD+oc5FwZARA/AEgEjoyEH8AiISO
DMQfACKhIwMQf4BI6MgAxB8AIqEjA/EHgEjoyED8ASASOjIA8QeIhI4MQPwBIBI6MhB/AIiEjgzE
HwAioSMDEH+ASOjIAMQfACKhIwPxB4BI6MhA/AEgEjoyEH/8CIBI6MgAxB8gEjoyAPEHgEjoyED8
ASASOjIQfwCIpD47Mi9eK/kCQCTAETUAIBIARAIAiAQQCQAgEkAkAIBIAJEAACIBQCQAgEgAkQAA
IgFEAgCIBBAJACASAEQCAIgEEAkAIBKoPYHwzCgAoOcDIgEARAK1IRMAQCQAiAQAEAkgEgBAJIBI
AACRQLPJBAAQCQAiAYDGFwm1vXnxog48IBKOegHoM4BI6BAAyASgjkRCRwCgDwEioRMA0IcAkdAJ
ABAJACIBQCQAiAQA6EOASOgEAPQhQCR0guZjbm6OH6FOfwf6ECCSQCf48eOH2bFjx5LPv379Gvzf
vg8fPjTbtm0za9asMR0dHWZ2dpYk8b88efLErF692uzZs8e+129Ub+1xl1Wp5S7X74BIAJEsUyf4
9euXOX78eOI0Y2Nj5sSJE6nzvnz50uzbt88sLCyY379/m+HhYbNz506SxP8iiTx9+nTZk1G1RNLM
SRmRACLxdIKDBw+a9+/fJ07T399vbt26lTpvV1eXGRgYyLUd09PTpqWlxezdu7fw+dWrV82GDRvM
unXrzPnz54vm+fnzp+nu7jZr1641bW1tZmpqquj7ixcv2vn0vdry4cMH7/okvDNnzpj169eb1tZW
e0bltj06i1i1apXZtWuXmZycTG3Pu3fvzLFjx+y6NY+2b3R0tLDuLM9w8rU97fdyCbUnab/Gv79/
/77ZtGmT3YazZ8/aM9TQGYlvv+T5XbL8Dnn2CSIBRLICnWBiYiJ1Gp2pHD582HZwJSolbZetW7fm
ut6tdShRKfl9/PjRfnbnzh1z7949+5nOjpQIr1+/XpjnypUrZmRkpHCG5J7x3LhxwwwODtp59dKy
lNx867t586a5du2a/ezz58/mwIEDRW13zyLGx8fN9u3bU9uze/duexYWrV/boqSf9rvH34fanrT9
cULtySISXXqTgLUMJfRz584FReLbL3l/l9DvkGefIBJAJCvYCZKm2bx5s3nw4EHhyPfu3bs2gbgd
XB1bR5w6+tRlsC9fvnjX4Z4xCCUxLdvFTRRKUPHvI9rb2+2RsXuUrCNr3/p0ZO/OMzMzU9R2Jbwo
QZaCjpqziiTU9qTtjxNqTxaRuGcT379/N1u2bAmKxLdf8v4uod+h3H2CSACRrKBIki6jSC7uPD09
PXZQPjoj0OWuPOuQjOKXO9yko++zJKek6dPWF2+TO53EGB2l9/X1BX8TXXqSXNVuic2XxOPvQ23P
sk9C7ckikngST/sN42dulfpdQr9D3n2CSACR1LBI4slbl7vco2ElJN8dOUnrSJKBL1GGvgsl0dA8
URLU5ZrOzk7T29ubun6NLejIfGhoyF4i1OWnPCIJtb0UkWT5DfL8RqWIJO/vEvod8uwTRAKIpMZE
ostE3759K7p0pMtYEUeOHFlyNKxLXHnWocFTndGkoduS0y6haN74pS1XZEnr011m7jyvX79O/X10
K7Pvt5NI3W3X3Wt5RBJqe5b9FmpPfBlJ2+jesq1Lk2pXSCS+/ZL3dwn9Dnn2CSIBRFJjIrlw4YId
fI0GTTUAevv27cL3um6tV/S97vDS/yXJsw4NmEeDxXrpve6+itDlEV3aEM+ePVsy2K51RvNq29z/
D5O0Pg0C6260aHD60KFDS6796y4hoQFe35G3bjaI7kZSAlfbfQlTktWYR5T4Q23Pst9C7XEHqnV3
nu6mim+j1ql5tYxLly7ZmyxCIvHtl9Dvkvd3yLNPEAkgkhoTiW4DPX36tD3K37hxo+3scZTINRiq
aZSk3rx5k3s7Ll++bI9io2W4dyhpGzSIr+Sha+0aTHaJbv/VS3dsvX37Nrg+3bKssy3djaZxHXc6
XULRenS5ReuMElgSz58/t4PCmk7JTlL1iUQiVhvdsyZf27MmL197osSr9kiyak98G5X0Nfal/aiD
B/eGibT2+PZL6HfJ+zvk2SeIBBAJnQCIDX4nQCR0AiBB8jsBIBJoGurxuVf0IUAkdAIARAKASAAQ
CQAiAQD6ECASOgEAfQgQCZ0AAJEAIBIARAKASOjsAMQWIBI6AZ0diC1AJMvcCUopfat59HhwPdtJ
z9969OiRfcienpMUr1Eukkrh6onCKp7klnQVeoifngSbZTtCJWYBEAkgkmUSSd7St5rn1KlT9rv/
/vvPJnI92FHv409m9ZXCVUEsfe+isrGSR5btCJWYBUAkgEiWSSR5S9/G59F7t5aEuy5fKdz5+Xl7
VhKtS/9u27atsOzQdoRKzAIgEkAkyySSOHnLv/reh0rh/vnnn/asQ6iuhh4fnnU7QiVmARAJIJIV
Ekne8q++96EysCqdGlVc1NiIyrJm3Y4sJXMBEAkgkhUQSd7yr773oVK4QtX0NN6hy1p5tiNPyVwA
RAKIZBlFkrf8q+99qBSu0AC67rpyB9KzbEeoxCwAIgFEskIiEXnKv4be+0rhisXFRbseySDPdghf
iVkARAKIhE4AQB8CREInAEAkAIgEAOhDgEjoBAD0IUAkdAIA+hAgEjoBACIBQCQAiAQAkQAAfQgQ
CZ0AgD4EiIROAIBIABAJACIBQCQAQB8CREInAKAPASKhEwDQhwCR0AkAEAkAIgEA+hAgEjoCAH0H
EAkdAoA+A4ikpjsGL168sr0AEAlw5AsAiAQQCQAgEgBEAgCIBBAJACASQCQAgEgAkQAAIgFAJACA
SACRAAAiAUQCAIgEEAkAIBIARAIAiAQQCQAgEkAkAIBIAJEAACIBRAIAiAQAkQAAIgFEAgCIBBAJ
ACASQCQAgEgAEAkAIBJAJACASACRAAAiAUQCAIgEAJEAACIBRAIAiAQQCQAgEkAkAIBIABAJACAS
QCQAgEgAkQAAIgFEAgCIBBAJACASgJIEEn8BACIBQCQAgEhgZWQCAIgEAJEAACIBRAIAiAQQCQAg
Emg2mQAAIgFAJACASGohofJqnhcQ98Q9IuGoHNjn/AZQgX1OFNCZgH1P26GsfU8k0JmAGKDNUFYM
EA10KCAGaDMgEjoUEAO0GRAJHQqIAdoMiIQfE4gB2gyIBOhQQAzQZkAkdCggBmgzIJIG6lA/fvww
O3bsWPL5169fg/9r9OHDh2bbtm1mzZo1pqOjw8zOzpJwaGNdx73LyMhI4nIuXrxo1q9fb9auXWtO
nDhhPn36REwgkubtUL9+/TLHjx9PnGZsbMx2kjRevnxp9u3bZxYWFszv37/N8PCw2blzJx2KNtZ1
3Ee8f//eHDx4cMk0AwMDZnBw0Ma8Xv39/XY6YgKRNG2HUgdQh0maRh3k1q1bqfN2dXXZTpVnO6an
p01LS4vZu3dv4fOrV6+aDRs2mHXr1pnz588XzfPz50/T3d1tj/za2trM1NTUkiNDzafv1ZYPHz54
16eOf+bMGXs02draas+o3LY/efLErF692qxatcrs2rXLTE5OIpImi/uIzs5O8+bNmyXTbN++3Xz/
/r3oM8UMcY9ImrZDTUxMpE6jI7bDhw/bYFcAKnhdtm7daubm5nJtx9mzZ21Qf/z40X52584dc+/e
PfuZjhIV4NevXy/Mc+XKFXt5ITpDcs94bty4UXRkqGWp8/nWd/PmTXPt2jX72efPn82BAweK2q7O
9PTpU/v3+Pi4TRqIpLniPjqIUmyFlqPLvxKCDqqIe0TS9Jc1kqbZvHmzefDgQeGI5u7duzbA3eBT
0OmIKbpW/OXLF+863CMnsWfPHrvs+BFfhDpQ/PuI9vZ2e+TmHsVt2rTJuz4dobnzzMzMFLVdR3FR
B+bSVnPGvS7Z6gAqtJyTJ0/aswK9Xr16RdwjEjpUlmkU2JKLO09PT489KouOjEJHZnEko/hgvk6v
s1wycKdLmj5tffE2udNJjHqvjt7X14dImizuv337ZpOuO3geWo7O1HU5iLhHJHSojInGDWJd7nKP
chScunsrzzqSOoWvA4S+KwqcDB0qaTpdX9blBF0j7+3tRSRNFPenTp0yjx8/zrUcXZoKjZEQ94ik
aUWi02Udobmn0LqMFXHkyJElRzm6xJVnHTqS0xlNGro9M+0UX/PGT/FdkSWtT3eZufO8fv069ffR
rcyNkoARSbZpshRL0mUgjTOkXVoi7hEJHcrhwoULdiAxGtTTYODt27cL3+uaql7R97rDS/+XJM86
NHAYDQLqpffurZQak9Fpt3j27NmSQUetM5pX2+b+v4Ck9ekWZQ2kRoOOhw4dKppOy9cdLEKDj74j
Q0TSHGfi8Wl0KUuXf6K4u3Tpkn0R94iEDpUwjf7D1unTp+3RzsaNG23gx1FA6whN0xw7dszeLpl3
Oy5fvmwvk0XLiO40ibZBg/gKbA0yapAw3qmjAU/dufL27dvg+nTLso4gdTeaxnXc6XR6r/Xo0oPW
GXUuRIJI3EtZuitK8aq4i9/NSNwjkqbtUEAM0GZo5BggGuhQQAzQZkAkdCggBmgzIBI6FBADtBkQ
CT8mEAO0GRAJ0KGAGKDNgEjoUEAM0GZAJHQoIAZWvE2+dhH3gEhIIkAMZBJJ2qNMiHtAJCQR2l2F
38L3LKlGfNVLrK30/IgECDLazRnJCp+RIBJE0rRJxFde01fqs5TSoaHvtUxVjFPVxeh5P1HFtizz
h0qJEgOMkWSJJRWr0kMS3T4SPeU61Cd863U/yxKrxDoiqZsk4iuv6Sv1WUrp0ND3WqYeXBdVdos/
gTQ0f6iUKDHAXVtZYknxrCdY6zs9OFF9Yn5+PlOfyCqSUKwS64ikrjqUr7ymr9RnKaVDQ98nLdPd
7tD8oVKixAAiyRpLSuRK1kre586dy9wnsookFKvEOiKpqw7lK6+Zt+JbltKhvu9DnS9vadJ4KVFi
AJFkjaUomeuR64uLi7n7RJZY9sUqsY5I6i6JpJXXrHTp0ND3oc5XSmlSOhciKSUWxdGjR+0ZyHKI
hFhHJA2TROLlNX2lPkspHRr6PtT5QvPnKSVKDDR3m0OxpIqDGqMYGhoqurSVtU/E17uwsFD0WShW
iXVEUlcdylde01fqs5TSoaHvQyIJzR8qJUoMIJIssaTB9v379xcl9ajqZ9Y+4d7E8v79e3sTift9
KFaJdURSVx3KV17TV+qzlNKhoe9DIsmyfF8pUWIAkWSJJcW8e/uv/tb3efpEdFCmfqWzGPWr+LaE
YpVYRyQkESAGaDMgEjoUEAO0GRAJ0KEAkQBxj0joUEAM0GZAJHQoIAZoMyASOhQQA7QZEAk/JhAD
tBkQCdChgBigzYBI6FBADNBmQCR0KCAGaDMgEjoUEAO0GRAJ0KGAGKDNgEjoUEAM0GZAJHQoIAZo
MyASOhQQA7QZEAnQoYAYoM2ASOhUwL6n7VClfU8k0KmAfc5vAGXtc6Kgwj8wr+Z5AXFP3CMS4KgU
ACqRA/gJAJEAACIBRAIAiAQQCQAgEkAkAIBIABAJACASQCQAgEgAkQAAIgFEAgCIBACRAAAiAUQC
AIgEEAkAIBJAJACASAAQCQAgEkAkAIBIAJEAACIBRAIAiAQAkQAAIgFEAgCIBBAJACASQCQAgEgA
kQAAIgFAJACASACRAAAiAUQCAIgEEAkAIBIARAIAiAQQCQAgEkAkAIBIAJEAACIBQCQAgEgAkQAA
IgFEAgCIBBAJACASAEQCAIgEEAkAIBJAJACASACRAAAiAYIIkQAgEgBEAgCIBBAJrNj+59U8L0QC
iATY91DxfU4UAMkE2O9Q1r4nEoCEAuxzKCsGiAYgqQD7HBAJkFSAfQ6IBEgqwD4HRAIEFLDPAZEA
kFSAfQ6IBEgqwD43Zm5urqaWU+1lIhIgqUDD7fORkZHgdE+ePDGrV682e/bsyZ+8Astes2ZNRdpa
qeX4lpm1D9VSX0MkgEigqvv8/fv35uDBg8HpJJGnT5+WlrwCy65UXFYjvktdJiIBRAJNs887OzvN
mzdvvNMlPcMp8fEbKfLIu2xx9epVs2HDBrNu3Tpz/vz5wucnT540z549KzpTOnLkSKbnTL17984c
O3bMrF271oqxra3NjI6OFm3L9PS0aWlpMXv37g22++fPn6a7u9suT8uamppKbXNae9yzvVWrVpld
u3aZyclJRAKIBOpjn/f395vBwcGSzhoqJZKk7+/cuWPu3btnfv/+bX79+mUePnxorl+/br/7+PGj
6ejosN/9+PHDbN++3czPz2daz+7du83w8LCdVy+1XdJwt+Ps2bP2O60n1O4rV67Yy4JibGzM7Ny5
M3E6X3viZ3vj4+O2TYgEEAnU/D5/+fKlOXz4cMnJvpoi0TiMkq6Lm1yVmG/evGmT8blz58qKb50F
uPN/+PAhc7sljvh2Jk0Xao9kFgmp2jFABgBEAhXZ59++fbOXbj59+lSTItERevyykpvwo+S8adMm
s7i4mCu+delKZxJdXV2mvb09uJ2+dms7s7Qp1B6dhegztamvrw+RACKB2t/np06dMo8fP84VG5UQ
Sdo4RnxZcWkkcfToUXtGkEck9+/ft/MMDQ2ZiYkJe/lqOUSSpT0SnC6Pacyqt7cXkQAigdre53mL
IWURycLCQsXOSDTg/PXr19Tpb9++bcccJIQ8l7bWr19ftFzfNmdp944dOzJd2gq1x2V2drbi/RSR
ACKBZdnnpVx+igaIdQux7oYqVSS660ljE7oLSty4ccNcu3atMCiu97pFWegsYv/+/UVJWnedJS0n
ztatWwt3ab1+/doO2oe2M77M+GC7LksJ3UmWNtjua4/QfLpzS+g39Z3pIBJAJNAwIokSni7b6Mhc
ibBUkWjQXP/xz/3Pf5cvX7ZnEPpMkoruojpx4kTR7b/6W9+nLcfl+fPndpBb263kHf+PmEnbGV+m
O43uGtP2aHkab5mZmUldVlp7hC5raX79llpWJBVEAogE2OdQczFANABJBdjngEiApALsc0AkQFIB
9jkgEiCggH0OiASApALsc0AkQFIB9jkgEiCpAPscEAmQVIB9DogEgKQCK77Py13XSs+PSADoaIBI
2OGIBBAJLOc+z1vOVmQtLxt6kq4eXnjmzBn7/KnW1lZbNTBPedrQ/MQ6IgFEAlXe56WWs81aXjYk
ElU4jJ6I+/nzZ3PgwIFc5WlD8wMiAUQCVd7npZazzVpeNiQSVWh0H/euJ+fmKU8bmh8QCSASqPI+
L7WcbdaqgCGRxJcjaeQpTxuaHxAJIBKo8j4vtZxttUQS/z60faH5AZEAIoEq7/NSy9lmLS8bKsW7
b9++oktTqliYpzxtaH5AJIBIoMr7vNRytlnLy4ZK8Q4PD5v+/v7CYPmhQ4dylacNzQ+IBBAJLMM+
L6WcbdbysqFSvGJgYMCOwegWXw3u5ylPG5qfWEckgEiAfQ6IBEgqwD4HRAIkFWCfAyIBIKmwz4EY
QCRAUgH2OSASIKkA+xwQCZBUgH0OiAQIKMKIfQ6IBICkAuxzQCRAUgH2OSASIKkA+xwQCZBUgH0O
iASApALsc0AkQFIB9jkgEiCpAPscEAmQVIB9DogEgKQC7HNAJEBSAfY5IBIgqUDT7/O5uTl+/Br5
bRAJIBKo2j6/ePGirYm+du1aW4f906dPFVuv6qxXMh4bKXaz/DaIBBAJ1Pw+HxgYMIODg+b379/2
1d/fbw4ePFizsdZIsbvcbUEkQGeEquzz7du3m+/fvxd9tnr16oqt031Fn01PT5uWlhazd+/eJdv2
7t07c+zYMXt2pO1oa2szo6OjwXZs27bNLC4u2r8XFhbsdC9fvrTvdYal77Ms/8mTJ/bzVatWmV27
dpnJyUlv++7du2e2bt1qp9d8T58+XXK2t27dOrs+CfrDhw+pvw0iAUQCdb/Pv379aq5evWq6uroy
yyGUCOPf6f3Zs2ft2c/Hjx+XTLN7924zPDxcOEPS2ZKkE2rH33//bR4/fmz/fvTokb1sdOfOncL7
7u7uTMt3ZTA+Pm5F62ubpBTJQfO5Er5x40bR2Z62J9oOzkgAkUDD7fOTJ0/aI2e9Xr16VbX16n2U
eLNum472Q9Pev3/f9PT02L///fdfK8NIiKdOnTIPHz7MtHxJZWRkJHPbfG1pb283P3/+LLzX35s2
bUIkgEigsfe5LsXokk41RRKaRpe+rly5YkWgZFyUAFPaMT8/b882hLZ/dnbWbNmyxb7X5Std7sqy
fJ2F6P2ePXtMX19f7t/U/cwVlHvGg0gAkUBD7/Nfv355x0gqcWnLN43OLHbu3GmGhobMxMSEvfyV
RSRi48aN5vPnzwWBaOzi9evXhfdZlh+JZmxszHR2dpre3t6SRZL0O2ZtCyIBRAJ1s891KUfJN+3y
y3Kfkeg2ZI3VREQD51li9/jx4+aff/4pXNKKLm+5Yz6h5bvorCaPJOOf6cwofmnLveUXkQAigYbY
57qUpUs40YDwpUuX7KtS6G4ljSNECTWUfHUWEd1FpbOJjo6OzCK5deuWleDt27ft+7t379r1686q
rMvX2Yru3BLxwfO8ItFgu7Yp+m21XTt27Ej9bRAJIBKoy32uS1m6i0pHyhpol1gqyfXr1+2yoyPx
UPJ9/vy5vVNKCVxJXQPfWUXy4sWLott+Z2Zm7Ps3b95kXr4ua2ncJLqdN5JKKSKJRB3dxKA7tt6+
fZv62yASQCTAPoe6iQGiAUgqwD4HRAIkFWCfAyIBkgqwzwGRAAEF7HNAJAAkFWCfAyIBkgqwzwGR
AEkF2OeASICkAuxzQCQAJBWoyX1erfVXs12N1k8QCdBBAJGwzYgE6CBQe/s8qfRtlnK3vhKzekDh
mTNn7JN2W1tbbVGptGdQxUvQRsvXY971AEY9Gl4VDvUARC0vvi53uaEyuar+uGHDBrve8+fPF32X
ZZsRCQAiYZ+nfB4vfZul3K2vxOzNmzfNtWvX7Lx6RP2BAweWPBU3VIJWVQ31QMn//vvPJvfTp0/b
9/F1xet/pJXJ1TokP61Py5Eo9NDErNuMSAAQCfvcI5J4udgk4uVufSVmdWbjPho9egpvRJYStPEz
FLeGSNrTgH1lclXxUJJwcUUT2mZEAoBI2OcekSSRt9ytrzKgEng5JWh977OWydXy41Ud3e0IbTMi
AUAk7PMcIiml3G2eErN5S9BmFUkkwKQyuUnyShNZo/YTRAKIBJZNJKWUu3U/27dvX9FlIlUiLKcE
bR6RRMTL5GqdbpvihLYZkQAgEvZ5DpGUUu7W/UwD9f39/YWB60OHDuUqQVuqSHxlcrXOaDBdL73X
3WJZtxmRACAS9nkOkZRS7jb+2cDAgB1A1+22umMqTwnaUkUSKpN7+fJle7alsx/ddRbdpZZ1mxEJ
ACJhnwMxgEiApALsc0AkQFIB9jkgEiCpAPscEAkQUPwI7HNAJAAkFWCfAyIBkgqwzwGRAEkF2OeA
SICkAuxzQCQAJBVgnwMiAZIKsM8BkQBJBdjngEiApALsc0AkACQVYJ8DIgGSCrDPAZEASQXY54BI
gKQC7HNAJAAkFWCfAyIBkgrU5T6fm5vjx0ckQFKBZtjnP378MDt27Kj4elUfvZLx2Eixu9xtQSSA
SKBq+/zXr1/m+PHjVYmLSi8TkSASQCRQg/v84MGD5v3791VJ+u4r+mx6etq0tLSYvXv3Ltm2d+/e
mWPHjpm1a9ea1atXm7a2NjM6Ohpsx7Zt28zi4qL9e2FhwU738uVL+/7Tp0/2+yzLf/Lkif181apV
ZteuXWZyctLbxosXL5p169bZ5el3/PDhQ9G23rt3z2zdutUuT8t9+vRp0fdv3741u3fvTpT7li1b
zLdv3xAJIBKo/X0+MTGROS7icnAlkWW9en/27Fnz+/dv8/HjxyXTKKkODw/b7/UaHBy00gm14++/
/zaPHz+2fz969MheUrtz507hfXd3d6blu8l+fHzcbN++PbVtN27csPNHy9L6ovVE2yppRXLRcrX8
eFsOHTq0RFgS0OnTpzkjAUQC9bXPl+PSlt67R+1Z1quj+dC09+/fNz09Pfbvf//913R1ddmXOHXq
lHn48GGm5UsqIyMjmdrW3t5ufv78WXivvzdt2pS5rdHfY2NjprOzs2g6na29evUKkQAiAUSSJJLQ
NLr0deXKFSsCJeuk5Btnfn6+cIlIl6RmZ2ftpSGhy1e63JVl+ToL0fs9e/aYvr6+zIJzz2iyttX9
W5e/1AYxMzNTuOyHSACRQMOJpBKXtnzT6Mxi586dZmhoyF5y0+WvLCIRGzduNJ8/fy4IRMn59evX
hfdZlh+JJjpL6O3tTV2fK42QKELf9/f3F86odHns7t27iAQQCXBGUopI1q9fb75+/Vp4Hw2cZ9lG
3Xn2zz//FC5pRZe3ovdZlu+isxrf+nTmE7+05d7unEckEqAG7HVjwIYNG+zt2IgEEAkgkv+PkqPG
CaKEG0quOouI7qLS2URHR0dmkdy6dcuOUdy+fdu+11G91q+B66zL19mK7twS8cHxOBps1zqjwXat
1/2/OHlEEp2J/PXXX/ZmhGrHABkAEAnUjUiuX79uj9KjI/VQcn3+/Lm9U0oJXEldA99ZRfLixYui
23411qD3b968ybx8XdbSuEl0u24klTSi23/1kgh0O2+pIpmamrKfVetpAIgEEAmwzxscjdfojGk5
YoBoAJIKsM8bDF0au3z5cvBOMUQCJBVgn0MiGss5fPhwVQbZEQmQVIB9DogESCrAPgdEAiQVYJ8D
IgEgqbDPgRhAJEBSAfY5IBIgqQD7HBAJkFSgYfa5njuV5yGMxBMiAaDjs8+L0FNuT5w4QTwhEgA6
PpS2z/X4cj14MCv6H9hnzpyxT9FtbW21BaOylMrNUlI2b5lbQCSASKAG9rkeva7/Ua1Hl0sOegih
j5s3b5pr165ZoejR5wcOHMhcKjdUUjZPmVtAJIBIoEb2+ebNm82DBw8KZxt69LqqB6ahyn1uDY7o
Cbs+okqCoZKyecrcAiIBRAI1us8lE8kljXh9Dk2fp1Sur6RsnjK3gEgAkUAN7/OkWuRpIokvO1TK
NlRSNmuZW0AkgEigRva5KgpqoDtCl600QJ7Gvn37ii5tqcpgnlK5WUvKhsrcAiIBRAI1ss8vXLhg
rl69WhgcV0XDqFRtEhpI11lFNNiuAfQ8pXKjM5GkkrJ5ytwCIgFEAjWyz3VGoLumVAp348aN9o6s
EAMDA/ZMRmcUd+7cyVUqV6SVlM1b5hYQCSASaNJ9Xu2SsoBIoMqBVM6jMACRlMtylJQFRAKIBBpY
JMtRUhYQCSyjTACRACIBQCSASACRACIBRAKIBBAJIBJAJEBSAfY5IBIAkgqwzwGRLP8Py6t5XiQR
IAYQCR0L2Oe0HRAJnQrY97QbEAkdCogB2gyIhB8TiAHaDIgE6FBADNBmQCR0KCAGaDMgEjoUEAO0
GRAJHQqIAdoMiASaqkPFS5Su9HKqvUxioDnaTFwjkobpUCq4s2PHjsTvLl68aNavX2+L85w4ccJ8
+vQpdTmqN62603v27Mm/kwPbqPralaBSy/EtM2sCW85Eh0j+j+/fv5uenh6zbt06u+8U11++fCGu
6zCuEUmNiOTXr1/m+PHjidMMDAyYwcFBWypUr/7+fnPw4MHUZamzPX36tLSdHAi+SgVnNYK81GUi
kpVp87lz58zt27cLca2DJcmEuK6/uEYkNSISieH9+/eJ02zfvt0evcU7Vdo64s94SlpmWifzbWPa
86OuXr1qNmzYYI8sz58/X/j85MmT5tmzZ0VHlEeOHMn0HKp3796ZY8eO2TMwtbWtrc2Mjo4Wbcv0
9LRpaWkxe/fuDbb758+fpru72y5Py5qamkptc1p73KPiVatWmV27dpnJyUlEUmKbN27caAXiHkyl
HdET17Ud14ikRkQyMTGRKdF8/frVBkRXV1fm9VSqwyV9f+fOHXPv3j2bEJQIHj58aK5fv26/+/jx
o+no6LDf6bKdhDg/P59pPbt37zbDw8OFo1Wdkalzudtx9uxZ+53WE2r3lStXzMjIiP17bGzM7Ny5
M3E6X3viR8Xj4+O2TYikMm1WUnT3MXFdP3GNSGqsQ/mm0ZGQjib0evXqVU10OF2vdo8qozMoN4Bv
3rxpg1aXMspJqDpacuf/8OFD5narg8W3M2m6UHvU6aOOy6Wtyrb5wYMHNjES1/UX14ikjkQSoWvJ
Ov2shQ6nI5n46bfbMaIg3rRpk1lcXMzVTp3iK7Ho7Ku9vT24nb52p10KTJrO1x4drekztamvrw+R
VKjNig0dKOlombiuv7hGJHUoEnW2rAFUaodLu94bX1a8cyVx9OhRe+SUp8Pdv3/fzjM0NGQv++k0
fzk6XJb2KBHoMkJnZ6fp7e1FJGW2WfH8999/m8+fP+daDnFdO3GNSOpAJDrtdDuZriXrSKjUDrew
sFCxIzedGWncJg3dlaNrs+o4eS4B6FZnd7m+bc7Sbt1WneUSQKg9LrOzs7nFgEiWnonoFmDt37zL
Ia5rJ64RSR2IRJeydLoZDdBdunTJvvKcpkcDabozTHeNlNrhdHeIruFKZuLGjRvm2rVrhW3T++jW
ZB1t7d+/vyiY37x5k7icOFu3bi3czfL69Ws7uBnazvgy44OSOn0XuuMmbVDS1x6h+XSHi9Bv6jsi
RCT+Nr948cL8+eef3v8TRVzXR1wjkjoQiU79dSeHbo3UQLvEkmcZUWDo9FZHMAqYUjucBhe1He5t
mpcvX7ZHWvpMnTm620T/J8C9TVJ/6/u05bg8f/7cDgZquxXkGggMbWd8me40urtG26Pl6br0zMxM
6rLS2hOd/mt+/ZZaVtT5EEn+Nm/ZsiVXWWLiunbjGpHUmEiAGKDN0MgxQDTQoYAYoM2ASOhQQAzQ
ZkAkdCggBmgzIBJ+TCAGaDMgEqBDATFAmwGR0KGAGKDNgEjoUEAM0GZAJHQoIAZoMyASoEOV3Pa8
JVSJAdrM74NICBjaXkTeEqrEAG0GRMKPGSNUftNXBjNUIrPU8prlLFcPhTtz5ox9rk9ra6utxpbW
9rTnLOl5Ylq2fhM9XM4t9hMvR0pSrb82b9u2rfD49egJuC9fvrTv9RBHfZ8l1tJiwTdPEqF405N+
9cDF6FlU8QMfrU/xrvLBqnoYb3No+ZVcFyJpUpGEym/6ymD6viunvGY5y1XluOhJo3r8/YEDB3I9
jE9PJtVvEP0eWp/qUrvTx8uRIpL6arPqjzx+/Nj+/ejRI/sgQe3n6H20v0OxlhQLoXniZIk3HehF
yT/+dFytS/U7onjXk4HjT94NLb9S60IknOIX4Rai8ZXB9H1XTnnNcparI0P3Mdp6ImkekegppO78
8forSeVIEUl9tVkFnlSHRPz777+2WqBe4tSpUzb5Z4m1pFgIzROnlHhz27Rv376iR+HH4z3L8iu1
LkTS5CLxld/0lcH0fVdOec1ylhuvZaBOnUckSdXc3GXWczJGJP/D/Py8PRMXunSqYkp6rLzQpd2o
0FUo1pKWnaVMbrnx5n4Wf2R8PN7zLL/cdSGSJhZJqPxmJJq0Mphp35VbXrPU5SYVxckjktD8iKQx
2qxr/Lo8EwlE4wIq9hS9zxJrScvOEvflxpuv3G08uedZfrnrQiRN3KFC5TddfGUw499Vqrxm3uXq
9Ns9lVdyyCMSLT9+KcA9EkMktdemPPs34vjx4+aff/4pXNKKLm9F77PEWtKy88R9qfHmfqYqh24p
7FevXi3pL1mXX+66EEkTiyRUftNXBtP3XTnlNctZrm4c6O/vLwwIHjp0KPdg+61btwrLV31sVcBD
JLUtkrQ78NLarH2ssQLtX3H37l17V5MGlLPGWtKyQ/MkTZ833tzP4gPgWld8sD3r8stdFyJpYpGE
ym/6ymCGSmSWWl6znOWKgYEBmyR0C6buUsl7xBrdLqmX7nB5+/ZtQ4kkLfk26isJ1Wx3b/uNBo6j
+udZYi1t2aH4LDfe4p/pwEmxrtvdFe/xsYysy6/EuhBJk4oEiIFmPCNpVFRH3R3naZR1IRKSCBAD
VRdJs8a9zrx1U0r0/1Z09hG/caUe14VISCJADNDmZUJ3Wur/TukSk+5Eu3Dhgk3y9b4uREKHAmKA
NgMioUMBMUCbAZEAHQqIAeIeEAkdCogB2gyIhA4FxABtBkRCh6oF5ubm2Ikk1WVpM7GGSKDCSaTU
/9yVZ74sD5Grh/9Bi0gao82ViLVm/k+RiIQOVZXkU6qAmj0JIpKVafNyxzwgkoboUKFyomnL8JXd
TCqYo+f86MF4R44csc82ynpGEn/8RVRLwkX/MUqPa/j27Rs7m+QWbHNaOeekR62EnkEVKu+c1G9K
KUENiKRmO1SWcqJJf4fKbsb/jqqraXqVOVUluqwiif+tJ/rGO5i25/Tp0+xoRJKpzb5yzvF5QiIJ
lXd2/y6nBDUgkprtUFnKiSb9HSq7Gf/bPQPR+rTeUkUSFbxy0aMbVB8BEEmWNvvKOecVSai8s/t3
OSWoAZHU9JFZ1nKiecpuhgYbs5T79C1DdVRUMjXquOrMgEiyttlXzjmvSEKVA+PTllqCGhBJzXao
POVES+08SevOUqXNtwzVRejp6bF/a+xFhYkAkeRpc1o553JF4ovdcktQAyKpyQ6Vp5xonrKb8b+j
swehywBuHYNSRKJ1a+Bel9c0cKnaCIBISmlzvJxzSCTxctSh8s7VKEENiKSmOlSecqJ5ym7G/z58
+LBZXFy002t9eQfbJQ3d+eV2WJ2J/PXXX+bs2bPsYESSq82+cs7xWHMHwN+/f2+rHrrLDZV3jpe+
LbUENSCSmk4iWcuJ5im7GZ9P32taTSOpqKPmEYnubNG87jqmpqbsNPxPZESSt82+cs7xWIsSuqZV
vXNNG1+ur7xzfNpSS1ADImn4JLISZTfVATXoDoiENgMiqcMOtdJlN7VeHdlxZwtJlTYDIqnTDrXS
ZTd1HVuXyBhkJ6nSZkAkdCggBmgzIBI6FBADtBkQCR0KiAHaDIgE6FBADNBmQCR0KCAGaDMgEjoU
EAO0GRAJHQqIAdoMiAToUEAMEPeASOhQQAzQZkAkdCggBmgzIBI6FBADtBkQCdChAJEAIgE6FBAD
tBkQCZ0K2Pe0HVZq3xMJdCpgn/MbQFn7nCio8A/Mq3leQNwT94gEOCoFgErkAH4CQCQAgEgAkQAA
IgFEAgCIBBAJACASAEQCAIgEEAkAIBJAJACASACRAAAiAUAkAIBIAJEAACIBRAIAiAQQCQAgEgBE
AgCIBBAJACASQCQAgEgAkQAAIgFAJACASACRAAAiAUQCAIgEEAkAIBJAJACASAAQCQAgEkAkAIBI
AJEAACIBRAIAiAQAkQAAIgFEAgCIBBAJACASQCQAgEgAEAkAIBJAJACASKDmBBJ/AQAiAUAkAIBI
YGVkAgCIBACRAAAiAUQCAIgEEAkAIBJoNpkAACIBQCQAgEhqIaHyap4XACASjsqBfQ6ASEgowL4H
QCQkEiAGABAJSQSIAQBEAiQRIAYAEAlJBIgBAERCEgFiAACRkESAGABAJNBQSWRubo4dhUgAEEm9
JZGk/wm9atWqktfz5MkTs3r1arNnz57c865Zs6ai7SRxIhIARLICSeS///4zly9fLnk9ksjTp09X
LNGRLPltABDJCiaR379/m927d5tv3755p7t48aJZt26dWbt2rTl48KD58OFD4tmN74xFZz27du0y
k5OTqfMmLcP9TNt75swZs379etPa2moePnzoPSO5evWq2bBhg9328+fPZ9ouRAKASCBHErlz507w
bOTGjRtmcHDQJnG9NE93d3fm9bhnLOPj42b79u2p84ZEcvPmTXPt2jW7HZ8/fzYHDhxIFYm28969
e3baX79+Welcv34903YhEgBEAhmTiM5GFhYWvNO0t7ebnz9/Ft7r702bNmVeT0tLixkZGcm0jSGR
7N27t2hbZmZmUkWiMRtJxMWVhW+7EAkAIoEMSWR+ft50dHQEl5M0EK+j+azr0dG+plFi7+vrK0sk
7nqFRJEmEk3ru6nAt12IBACRQIYkcuvWLTv2ESKevOPLzpKspqenzdjYmOns7DS9vb0VE4lvW7Lc
iZa2XYgEAJFAhiRy/Phxm0RDaCA6fmnLvW03T7KanZ31Sij+Xpfd3M/27dtXtC2vX79OXZ62++vX
ryVtFyIBQCSQIYlovODjx4/B5WiwXWcv0WD77du3zY4dOzKvZ+fOnfYOKaHBbfesQneB6Q6wSA7u
APj79+/NsWPHipY/PDxs+vv7C4Pthw4dShWJtjsamNdL73XHWZbtQiQAiARMtrup4oPRaUS3/+ql
O7bevn2beT26fKQBe11q0jqj5C10F5XObqIznCiha1rJStPGlz8wMGAH+3Vbr+7M8p3h6I403Sqs
5UtKrjh924VIABAJkESAGABAJCQRIAYAEAlJBIgBAERCEgFiAACRkESAGABAJEASAWIAAJGQRIAY
AEAkJBEgBgAQCUkEiAEARALlJJFKJZdyl1PN+Umg/A4AiKQOkkgtiwT4jQAQyTKdkehvVRHcunVr
4ZlTbv11PUxRz9bSwxXb2trM1NRU6nJ86wmVyBW+srhZ5i+1jYgEAJFAmSLRwwyjGuzxp+BeuXKl
UEVQj5zXE3NLEUmoRG6oLG5o/nLaiEgAEAmUKZIowSZ9L3GkPSE4j0hCJXJDZXFD85fTRkQCgEig
TJH4vvcduZeznHiJ3FBZ3ND85WwbIgFAJFCHIol/HyqLG5ofkSASAERSoyJRcalSLm3lLZEbKosb
mh+RIBIARFKjItFg+/j4uP372bNnqYPt5ZbIDZXFDc2PSBAJACKpUZH8+PHDnDhxwopCZWk1yJ00
XbklcoWvLG6W+REJIgFAJCQRIAYAEAlJBIgBAERCEgFiAACRAEkEiAEAREISAWIAAJGQRIAYAEAk
JBEgBgAQCUkEiAEARAINkETm5uaqOj0gEgBE0iBJJO1/let/rOchPj1JEZEAIJImFEk520MSRCQA
iKSGk8jFixftc61aWlrM/fv3cz2b6t27d/ZZWCq/q+drqQTv6Oio94wkXmsktJyk6fXvt2/fzJYt
W+wzwFz0ZGA9QTjCV7aXGABAJFBmElHZ2uhJunowoqoP5hHJ7t277dN4oyf1Dg4OWiH5RJK03DzL
cd/39PTYpwPH2yR5iFDZXmIAAJFAmUlEZW3dI/qpqamyn5brFqbKKpI8y3Hfz8/P27OSqE6K/t22
bVuhnG6obC8xAIBIoMwkEipbm0Uk09PTtlZJV1eXfbx8FnkkLTfrcuLv//zzT3vWIXRWo0tkbvt8
ZXuJAQBEAhUWSZaE736mMRUVuBoaGjITExP28lgpIsmznPj7sbExO6YiNDai+ZPOaogBuhEgEqhC
Etm/f7/58uVL4X28bG2obK4G6d2yuPHvs4okz3KS3m/dutWOjeiylkuobC8xAIBIoMwk8vjxY3vX
VlrZ2lDZXCXw6O4qSaijoyOTPHR3lsYxotrroeXEp4+3RwPora2tSwbSQ2V7iQEARAIVSCK6s0l3
SG3evNkm8zxlc58/f24HrzWNLk2NjIxkEokSvv6TYfQfDUPLiU8fb8/i4qL9TjKMEyrbSwwAIBKo
cBIh4RADAIgEEAmwXwEQycolkbzPwQJEAoBISCJADAAgEiCJADEAgEhIIkAMACASkggQAwCIhCQC
xAAAIoGVTiKUxiUGABAJSaQslrM0LgmS3wkAkTRgEgk9ZBEQCQAiaZAkomdnRc/S0pNyJycnzdu3
b23FwjiqMKgiUipxq+WpBogetqh53Yc7ppXGvXXrVuL0Eb6SuEnbmdQ233TEAN0IEAlUIYm4CX18
fLxQPVBPAY4nYYnj9OnTheXpAYhRJcLo4Y6+M5KjR4+mTh8qiZu2nfF1+aYjBuhGgEigCklET/3V
k3bjqFhUZ2dn0Weq5/7q1avC8iIpJK0jSSS+6UMlcdO2M74c33TEAN0IEAlUIYnoqF3fKZH39fUV
fafLUKqJLmZmZqxIfMvLU4gq6UzCVxLXt53ucnzTEQN0I0AkUKUkolrp0RlIb29v4fP+/n7T09Nj
/+7u7jZ3796tmkiylMRN286kGvJJ0xEDdCNAJFDlJDI7O1s0nYpEqTLhp0+f7CD4jx8/qiaSPCVx
49uZ1rb4dMQAvwUgEqhCElE1Qt3pJOID4NGZyF9//WXOnj2bSwyh0rjxz0IlcX3b6S4n1B5iAACR
QIWTiC4Dtbe3F27JjZJwxNTUlJ03/j/VQ2IIlcZN+sxXEte3ne5yQu0hBgAQCSxzElEy16A7IBIA
REISyT2PLjHpLIG7nxAJACKBkpKIxjkOHz5cNMgOiAQAkZBEgBgAQCRAEgFiAACRkESAGABAJCQR
IAYAEAlJBIgBAEQCJBEgBgAQCUkEiAEAREISAWIAAJGQRIAYAEAkQBIBYgAAkZBEgBgAQCQkESAG
ABAJSQSIAQBEAiQSYN8DIBISCrDPARBJ7SUWXs3zAgBEAhyZAwAiAUQCAIgEEAkAIBJAJACASAAQ
CQAgEkAkAIBIAJEAACIBRAIAiAQAkQAAIgFEAgCIBBAJACASQCQAgEgAEAkAIBJAJACASACRAAAi
AUQCAIgEAJEAACIBRAIAiAQQCQAgEkAkAIBIABAJACIBQCQAgEgAkQAAIgFEAgCIBBAJACASAEQC
AIgEEAkAIBJAJACASACRAAAiAUAkAIBIAJEAACIBRAIAiAQaUiDxFwAgEgBEAgCIBFZGJgCASAAQ
CQAgEkAkAIBIAJEAACKBZpMJACASAEQCAIikFhIqr+Z5AQAi4agc2OcAiISEAux7AERCIgFiAACR
kESAGABAJEASAWIAAJGQRIAYAEAkJBEgBgAQCUkEiAEARAINlUTm5ubYUYgEAJHUWxL58uWLOXbs
mFm7dq1Zt26dOXnypPn8+XPJ63ny5IlZvXq12bNnT+5516xZU9F2kjgRCQAiWYYkcvXqVdPX12d+
//5tXw8ePDCXL18ueT2SyNOnT1cs0ZEs+W0AEMkyJ5HDhw+b169fF97/+vXLHDlyxLusixcv2rMX
ncUcPHjQfPjwobCO0DOeojOWVatWmV27dpnJycnUeZOW4X4m8Z05c8asX7/etLa2mocPH3rPSCTN
DRs22G0/f/58pu1CJACIBAJJRElYCTn+WRo3btwwg4ODhTOYO3fumO7u7szJyj1jGR8fN9u3b0+d
NySSmzdvmmvXrtnt0OW4AwcOpIpE23nv3j07rWQp6Vy/fj3TdiESAEQCniSiBJrls4j29nbz8+fP
wnv9vWnTpszJqqWlxYyMjGTaxpBI9u7dW7QtMzMzqSLRmE1cmK4sfNuFSAAQCXiSiC7l5BFJaPpQ
stLRvqZRYtfYTDkiiW+nRJEmEk0bv3zmtsW3XYgEAJGA8V/ayvKZTzJ575Sanp42Y2NjprOz0/T2
9lZMJL5tSRJg1u1CJACIBDxJREnz+/fvhfc/fvywA+hpaCA6fmnLvW03T7KanZ31Sij+fmFhoeiz
ffv2FW2LbhpIW562++vXryVtFyIBQCRg/Lf/RgPWeg0NDXkv7Wiw/datW4Xpb9++bXbs2JE5We3c
udPeISU0uO2eVeguMN0BFsnBHQB///69/f8u7vKHh4dNf39/YbD90KFDqSLRdrvt1HtXmL7tQiQA
iAQ8SeTjx482AeusQq+jR4/a/6ToI7r9Vy/dsfX27dvMyUqXjzRgr0tNStZR8ha6iyraDjeha1rJ
StPGlz8wMGAH+3Vbr+7M8p3h6P/H6LKdli8pqe1ZtguRACASIIkAMQCASEgiQAwAIBKSCBADAIiE
JALEAAAiIYkAMQCASIAkAsQAACIhiQAxAIBISCJADAAgEpIIEAMAiATKSSKVSi7lLqea85NA+R0A
EEkdJJFaFgnwGwEgkmU6I9HfqiK4devWwjOn3Prrepiinq2lhyu2tbWZqamp1OX41hMqkSt8ZXGz
zF9qGxEJACKBMkWihxlGNdjjT8G9cuVKoYqg6nboibmliCRUIjdUFjc0fzltRCQAiATKFEmUYJO+
lzji5WpLEUmoRG6oLG5o/nLaiEgAEAmUKRLf974j93KWEy+RGyqLG5q/nG1DJACIBOpQJPHvQ2Vx
Q/MjEkQCgEhqVCQqLlXKpa28JXJDZXFD8yMSRAKASGpUJBpsHx8ft38/e/YsdbC93BK5obK4ofkR
CSIBQCQ1KpIfP36YEydOWFGoLK0GuZOmK7dErvCVxc0yPyJBJACIhCQCxAAAIiGJADEAgEhIIkAM
ACASIIkAMQCASEgiQAwAIBKSCBADAIiEJALEAAAiIYkAMQCASKCBksjc3FxJ31ViemIAAJFAAyQR
/c/1tO2Mf1fOsoDfA4Ae0KBJpJK11kmU/D4AiGSFksjFixftc61aWlrM/fv3cz2b6t27d/ZZWCq/
q+drqQTv6Oho0bRppW3jNUfcZSd951tX2rK+fftmtmzZYp8T5qKnB+spwxG+0r6IBACRgCeJqGxt
9CRdPRhR1QfziGT37t32abzRk3oHBwetkNxpfaVt48v3rTvLupKW1dPTY58gHG+35CFCpX0RCQAi
AU8SUVlb92h9amqq7KfluoWpQqVt84gky7qSljU/P2/PSqJaKvp327Zthe0KlfZFJACIBDxJJFS2
NotIpqenba2Srq4u+3j5PPPnFUmedbnv//zzT3vWIXRWo7Mk9zfwlfZFJACIBHKIJEsydz/TmIoK
XA0NDZmJiQl7eaxaIsm7Lvf92NiYHVMRGhvR/ElnNc0YAwCIBMpKIvv37zdfvnwpvI+XrQ2VzdUg
vVsWN/59JUWSd13x9xrw19iILmu5hEr7IhIARAKeJPL48WN711Za2dpQ2Vwl5+jOKUmoo6Mjl0h0
B5bGKqIa7L7vQuvyLUtoAL21tXXJQHqotC8iAUAkEEgiumtJdz9t3rzZJuo8ZXOfP39uB6Y1jS47
jYyM5BKJkrr+I2H0nwl934XW5VuWWFxctN9JmHFCpX0RCQAi4QfMkURIOMQAACIBRALsVwBEsnJJ
JO8zrgCRACASkggQAwCIBEgiQAwAIBKSCBADAIiEJALEAAAiIYkAMQCASGClkwhlb4kBAERCEimL
5Sx7S4LkdwJAJA2YREIPUAREAoBIGiSJ6NlZ0bO09BTcyclJ8/btW1uNMI6qB6pAlMrXllJC99at
W4nTR/jK3SZtZ1LbfNMRA3QjQCRQhSTiJvTx8fFCZUA9BTiehCWO06dPF5aXt4Tu0aNHU6cPlbtN
2874unzTEQN0I0AkUIUkoqf+6im6cVQIqrOzs+gz1XN/9epVYXl5S+j6pg+Vu03bzvhyfNMRA3Qj
QCRQhSSio3Z9p0Te19dX9J0uQ6neuZiZmbEi8S0vT5GppDMJX7lb33a6y/FNRwzQjQCRQJWSiOqg
R2cgvb29hc/7+/tNT0+P/bu7u9vcvXu3aiLJUu42bTuTasgnTUcM0I0AkUCVk8js7GzRdCoApaqD
nz59soPgP378qJpI8pS7jW9nWtvi0xED/BaASKAKSUSVBnWnk4gPgEdnIn/99Zc5e/ZsLjGEyt7G
PwuVu/Vtp7ucUHuIAQBEAhVOIroM1N7eXrglN0rCEVNTU3be+P9UL6eEbtoyfOVufdvpLifUHmIA
AJHAMicRJXMNugMiAUAkJJHc8+gSk84SuPsJkQAgEigpiWic4/Dhw0WD7IBIABAJSQSIAQBEAiQR
IAYAEAlJBIgBAERCEgFiAACRkESAGABAJFDLSYSSu8QAACJpgiSiJ+aqVkg1iJfcbdQEm3UZ+h/7
z549QyQAiKSxRKJHrkePi2/G5LWc26jf2X0cPyIBQCR1L5IXL17Y/3QYn3ZoaMhs2rTJbNy40Tx6
9Mg+RFHPwcpTIjep5O67d+/sUbn+s6OW1dbWZkZHR73bHprHV/Y36/xZygtXqtyvfm/97ogEAJE0
hEjOnTtn7t+/v2TaU6dO2ST633//WYGoxK7e5y2RG1+vkvXw8HDhKb+Dg4O2qqGP0Dyhsr9Z5heh
8sKVKvcrSet3RyQAiKQhRNLR0WFev369ZFq3LK7eu7VC8pTIzZK8shS18s0TKuObZX4RKi9cqXK/
+r31uyMSAETSECLR5Z64CEJFqfKUyE1arx71fuXKFdPV1WUf+Z4lwfnmyfKI+qzz+8oLV6rcr35v
XQZEJACIpCFEknQ2kEckobOJ+Ly6jKbiU7q8MzExYR9TH02TNKYSmieLSPLM7ysvHAmpEuV+V6Lg
FiIBRAI1eUYSKpEbn1fjLe70CwsLwQQXmickkjzz+8oLu5RT7ldjSZyRACCShhGJrtXrEk6pIgmV
yI2X3NWlo+iOqWisIJTgQvOERJJ3/rTywpUq96sxF8ZIABBJw4hEdw/pzqtSRSJ8JXLjJXefP39u
B+OVXJVwNSgdSnCheUIiyTt/WnnhSpX71eUy7toCQCQNIxIlTfcMAqpfXvjAgQNWNogEAJE0hEiE
7i7imVj/Q7XLC+vSmn7vWosBAEQCZSURXcfXmABUv7ywfmeetQWASBpOJEAMACASIIkAMQCASEgi
QAwAIBKSCBADAIiEJALEAAAiAZIIEAMAiIQkAsQAACIhiQAxAIBISCJADAAgEiCJADEAgEhIIkAM
ACASkggQAwCIhCQCxAAAIiGRAPseAJEACQXY5wCIZMUTC6/meQHA//D/ADmBoGMi1g2lAAAAAElF
TkSuQmCC
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-01-07 12:38:07 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-04-02 21:41:27 +0100" MODIFIED_BY="Graham Chan" NO="1">
<TITLE MODIFIED="2015-04-02 21:29:19 +0100" MODIFIED_BY="Graham Chan">Cochrane Epilepsy Group Specialized Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-04-02 21:41:27 +0100" MODIFIED_BY="Graham Chan">
<P>#1 MeSH DESCRIPTOR Diet Therapy Explode All</P>
<P>#2 MeSH DESCRIPTOR Fasting Explode All</P>
<P>#3 ketogenic* or diet? or dieting</P>
<P>#4 #1 OR #2 OR #3</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-04-02 21:41:52 +0100" MODIFIED_BY="Graham Chan" NO="2">
<TITLE MODIFIED="2015-04-02 21:35:14 +0100" MODIFIED_BY="Graham Chan">CENTRAL via CRSO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-04-02 21:41:52 +0100" MODIFIED_BY="Graham Chan">
<P>#1 MESH DESCRIPTOR Epilepsy EXPLODE ALL TREES WITH QUALIFIERS DH</P>
<P>#2 MESH DESCRIPTOR Seizures EXPLODE ALL TREES WITH QUALIFIERS DH</P>
<P>#3 #1 OR #2</P>
<P>#4 MESH DESCRIPTOR Diet Therapy EXPLODE ALL TREES</P>
<P>#5 MESH DESCRIPTOR Fasting EXPLODE ALL TREES</P>
<P>#6 (ketogenic* or diet? or dieting):TI,AB,KY</P>
<P>#7 #4 OR #5 OR #6</P>
<P>#8 (epilep* OR seizure* OR convuls*):TI,AB,KY</P>
<P>#9 MESH DESCRIPTOR Epilepsy EXPLODE ALL TREES</P>
<P>#10 MESH DESCRIPTOR Seizures EXPLODE ALL TREES</P>
<P>#11 #8 OR #9 OR #10</P>
<P>#12 #7 AND #11</P>
<P>#13 #3 OR #12</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-01-07 12:38:07 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2015-04-02 21:36:39 +0100" MODIFIED_BY="Graham Chan">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-01-07 12:38:07 +0000" MODIFIED_BY="[Empty name]">
<P>This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomised trials published in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>).</P>
<P>1. exp Epilepsy/dh [Diet Therapy]</P>
<P>2. exp Seizures/dh [Diet Therapy]</P>
<P>3. 1 or 2</P>
<P>4. exp Diet Therapy/</P>
<P>5. exp Fasting/</P>
<P>6. (ketogenic$ or diet? or dieting).tw.</P>
<P>7. 4 or 5 or 6</P>
<P>8. exp Epilepsy/</P>
<P>9. exp Seizures/</P>
<P>10. (epilep$ or seizure$ or convuls$).tw.</P>
<P>11. 8 or 9 or 10</P>
<P>12. exp *Pre-Eclampsia/ or exp *Eclampsia/</P>
<P>13. 11 not 12</P>
<P>14. 7 and 13</P>
<P>15. 3 or 14</P>
<P>16. (randomized controlled trial or controlled clinical trial).pt. or (randomi?ed or placebo or randomly).ab.</P>
<P>17. clinical trials as topic.sh.</P>
<P>18. trial.ti.</P>
<P>19. 16 or 17 or 18</P>
<P>20. exp animals/ not humans.sh.</P>
<P>21. 19 not 20</P>
<P>22. 15 and 21</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 of studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 of studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;13 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;156 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;156 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;230 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;3 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;143 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;4 full-text articles excluded:&lt;/p&gt;&lt;p&gt;3 = trial was not randomised&lt;/p&gt;&lt;p&gt;1 = trial was only 5 days&lt;/p&gt;&lt;p&gt;2 full-text articles were ongoing studies&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>